Sortilin inhibitors
Compounds targeting sortilin-ligand interactions inhibit sortilin activity, reducing cancer stem cell formation and treating neurodegenerative and autoimmune diseases by blocking progranulin binding, addressing the limitations of current treatments.
Patent Information
- Application Number
- JP2024533212
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-02
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
AI Technical Summary
Current treatments for diseases associated with sortilin activity, such as frontotemporal dementia, Alzheimer's disease, and cancer, lack effective compounds that can inhibit sortilin-ligand interactions, particularly the binding of progranulin to sortilin, which are crucial for disease progression.
Development of compounds that bind to sortilin with high affinity, blocking the interaction of progranulin and other ligands, thereby inhibiting sortilin activity, using specific aromatic and heterocyclic structures with unsaturated aliphatic moieties.
These compounds effectively reduce cancer stem cell formation and metastasis, and treat neurodegenerative diseases, psychiatric disorders, and autoimmune diseases by inhibiting sortilin-ligand interactions, offering therapeutic benefits.
Smart Images

Figure 2024542806000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to compounds suitable as sortilin inhibitors, and uses thereof. [Background technology]
[0002] Sortilin is a type I transmembrane protein that functions as a receptor for several ligands as well as in sorting cargo from the trans-Golgi network (TGN) to late endosomes and lysosomes for degradation. Sortilin negatively regulates the extracellular levels of the secreted protein progranulin (PGRN) by binding to it and targeting it for lysosomal degradation. PGRN is a secreted growth factor-like trophic and anti-inflammatory protein that also serves as an adipokine involved in diet-induced obesity and insulin resistance.
[0003] PGRN deficiency accounts for approximately 25% of all hereditary forms of frontotemporal dementia (FTD), an early-onset neurodegenerative disease. Patients with heterozygous loss-of-function mutations in PGRN have approximately 50% reduced extracellular levels of the protein and invariably develop FTD, making PGRN a causative gene for the disease. Furthermore, PGRN mutant alleles have been identified in patients with Alzheimer's disease. Importantly, PGRN acts protectively in several disease models, promoting behavioral recovery from ischemia, suppressing motor dysfunction in models of Parkinson's disease, reducing pathology in models of amyotrophic lateral sclerosis (ALS) and arthritis, and preventing memory impairment in models of Alzheimer's disease through increased PGRN levels.
[0004] Sortilin also binds proneurotrophins, such as pro-nerve growth factor (pro-NGF), pro-brain-derived neurotrophic factor (pro-BDNF), and proneurotrophin 3, which have prodomains and are generally pro-apoptotic. Such proneurotrophin precursors are released upon stress, and sortilin, in conjunction with p75NTR, is involved in regulating their release and stimulating apoptosis.
[0005] Sortilin also binds directly to p75NTR. Sortilin also binds to neurotensin in a region that overlaps with PGRN binding, and is therefore also referred to as the NTR3 receptor. Sortilin can also interact with the Trk receptors NTRK1, NTRK2, and NTRK3, regulating their anterograde axonal transport and signaling. Sortilin also interacts with the amyloid precursor protein (APP), regulating its processing and transport, and the resulting generation of pathological β-amyloid peptides.
[0006] Sortilin has been shown to bind to apolipoproteins and lipoprotein lipases, so that deficiency reduces the release of very low density lipoproteins (VLDL) from the liver and reduces cholesterol. Sortilin has also been implicated in direct binding to APP and binding to the APP processing enzyme beta secretase 1 (BACE1). Sortilin also binds to apolipoprotein E (APOE) and amyloid beta peptide. Sortilin has also been shown to bind to proprotein convertase subtilisin / kexin type 9 (PCSK9) to regulate extracellular levels, which directs the lysosomal degradation of the low density lipoprotein receptor and increases the levels of low density lipoprotein (LDL) cholesterol.
[0007] When present in intracellular vesicles such as endosomes, sortilin's amino-terminal extracellular domain is directed towards the lumen where the vesicular cargo resides. However, sortilin's carboxy-terminal intracellular / cytoplasmic domain binds to a series of adaptor proteins that regulate sortilin's trafficking from the surface and within intracellular compartments. These include clathrin adaptor protein 2 (AP2) and retromer complex / AP1, which regulate trafficking from early endosomes to the Golgi apparatus for recycling, and interactions with GGA (Golgi-localized, γ-ear-containing, ADP-ribosylation factor-binding) family proteins for direct trafficking from the Golgi apparatus to early endosomes, usually for subsequent degradation by lysosomes. Thus, while sortilin binds ligands at its luminal domain, it can also associate with cytoplasmic adaptors that determine its destination and fate within the cell, such as degradation of PGRN and other factors.
[0008] Sortilin and its multiple ligands through various interactions with proteins such as PGRN have been shown to be involved in various diseases, disorders and conditions such as FTD, ALS, ALS-FTD phenotype, Alzheimer's disease, Parkinson's disease, depression, neuropsychiatric disorders, vascular dementia, epileptic seizures, retinal dystrophies, age-related macular degeneration, glaucoma, traumatic brain injury, aging, epileptic seizures, wound healing, stroke, dermatology-related diseases, autoimmune diseases, arthritis, atherosclerotic vascular diseases and cancer (WO2009 / 140972, WO2014 / 114779, WO2016 / 164637, Breast Cancer Research2018 20:137, Bioorganic & Medicinal Chemistry Letters2020 30:127403).
[0009] Thus, there is a need for therapeutic compounds that bind to Sortilin and block binding of Sortilin to its ligands (e.g., PGRN) or otherwise modulate the effective concentration of the ligand in order to treat one or more diseases, disorders, and conditions associated with Sortilin activity. Summary of the Invention
[0010] It is a general objective to provide therapeutic compounds that bind to sortilin and block binding of sortilin to its ligands, such as PGRN.
[0011] It is a particular object to provide such therapeutic compounds that are useful in the treatment of diseases, disorders and conditions associated with sortilin activity.
[0012] These and other objectives are accomplished by the embodiments disclosed herein.
[0013] The invention is defined by the appended claims. Further embodiments of the invention are defined in the dependent claims.
[0014] An embodiment of the present invention is a compound of formula I [ka] (In the formula, A is a 5- or 6-membered aromatic ring, aromatic heterocycle, or heterocycle having 0-2 heteroatom(s) selected from N, O, and S, or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 heteroatom(s) selected from N, O, and S, and the aromatic ring, aromatic heterocycle, heterocyclic ring, or bicyclic ring A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; Y is absent, -O-, -OCH2-, -CH2-, -NR 3 - or -CH(NH2)-, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or 0-4 heteroatom(s) selected from among N, O and S, and the aromatic or heteroaromatic ring B is optionally selected from C1-C4 alkyl, -NR 1 R 2, -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; R 1 , R 2 , R 3 and R 4 are independently hydrogen or C1-C4 alkyl; Z is a halogen; R 5 is hydroxyl or C1-C4 alkoxy; or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
[0015] Another aspect of the present invention relates to a pharmaceutical composition comprising a compound according to the above and at least one pharma- ceutically acceptable excipient, carrier or diluent.
[0016] Further aspects of the invention relate to compounds for use as medicines, for use in the prevention or treatment of cancer, and for use in the prevention or treatment of neurodegenerative diseases, psychiatric diseases, motor neuron diseases, peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, cardiovascular diseases, dermatologically related diseases, autoimmune diseases, preferably Alzheimer's disease and Parkinson's disease.
[0017] The present invention also relates to intermediates for preparing the above compounds. (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexenoic acid, Ethyl (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexanoate, and ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate.
[0018] The compounds of the present invention are effective Sortilin inhibitors and bind to Sortilin with high affinity.The binding of Sortilin inhibitors to Sortilin blocks or at least significantly inhibits the binding of other ligands, such as Progranulin (PGRN), to Sortilin.Therefore, Sortilin inhibitors can be used to treat diseases, disorders and conditions associated with the binding of such ligands to Sortilin.
[0019] The present embodiments, together with further objects, may best be understood by reference to the following description taken in conjunction with the accompanying drawings, in which: [Brief description of the drawings]
[0020] [Figure 1A] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1B] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1C] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1D] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1E] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1F] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1G] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1H] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1I]1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1J] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1K] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1L] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1M] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1N] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1O] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1P] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1Q] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1R] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 1S] 1 shows the binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA). [Figure 2A] 1 shows the reduction of Progranulin-induced secondary sphere formation using a small molecule targeting Sortilin. [Figure 2B] 1 shows the reduction of Progranulin-induced secondary sphere formation using a small molecule targeting Sortilin. [Figure 2C]1 shows the reduction of Progranulin-induced secondary sphere formation using a small molecule targeting Sortilin. [Figure 2D] 1 shows the reduction of Progranulin-induced secondary sphere formation using a small molecule targeting Sortilin. [Figure 3A] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3B] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3C] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3D] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3E] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3F] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3G] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3H]FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 3I] FIG. 1 shows that reference compound RC3 has agonistic properties on sphere formation, unlike sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62. [Figure 4A] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4B] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4C] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4D] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4E] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4F] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4G] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4H]Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Figure 4I] Figure 2 shows cell viability upon exposure to reference compound RC3, and sortilin inhibitors SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI51. [Diagram 5] 1 shows that sortilin inhibitor SI5 reduced colon cancer cell sphere (SC) formation. [Figure 6] 1 shows that sortilin inhibitor SI62 reduced melanoma cancer cell sphere (MelS) formation. [Figure 7] FIG. 1 shows that the reference compound RC3 induces lung metastases in an MDA-MB231 in vivo xenograft model. [Figure 8] 13 shows that the sortilin inhibitor SI5 does not induce lung metastases in an MDA-MB231 in vivo xenograft model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] The present invention relates generally to sortilin inhibitors and uses thereof.
[0022] The sortilin inhibitors of the present invention can bind to sortilin and block or at least significantly inhibit the binding of other ligands, such as progranulin (PGRN), to sortilin. Thus, sortilin inhibitors can be used to treat diseases, disorders and conditions associated with sortilin activity.
[0023] Sortilin inhibitors are known in the art. WO2014 / 114779 and Bioorganic & Medicinal Chemistry Letters 2014, 24:177-180 disclose structurally unrelated N-substituted-5-substituted phthalic acids, including N-(6-methyl-pyridin-2-yl)-5-trifluoromethyl-phthalamic acid, also known as AF38469. AF38469 has a reported IC50 value of 330 nM for binding to Sortilin in the literature. Bioorganic & Medicinal Chemistry Letters 2020, 30:127403 discloses two series of inhibitors that disrupt the binding of PGRN to Sortilin. The best optimized compounds report IC50 values of 20-90 nM.
[0024] The sortilin inhibitors of the present invention differ from the optimized compounds disclosed in Bioorganic & Medicinal Chemistry Letters 2020, 30:127403, inter alia, in that they have an unsaturated aliphatic moiety in place of such a saturated aliphatic moiety. The experimental data presented herein shows that comparing two sortilin inhibitors that transition from a saturated aliphatic moiety to an unsaturated aliphatic moiety can unexpectedly increase the binding affinity of the sortilin inhibitor (decreasing the IC50 value).
[0025] Furthermore, AF38469 (herein referred to as RC3) had sortilin agonist properties when used alone, i.e., not in combination with PGRN. These agonist properties increased cancer stem cell (sphere) formation in vitro and induced lung metastasis in vivo. The sortilin inhibitors of the present invention do not have these agonist properties of AF38469, and when used alone, have sortilin antagonist properties that do not increase sphere formation, but rather reduce sphere formation.
[0026] definition The following abbreviations are used herein: ACN Acetonitrile ADP Adenosine diphosphate ALS Amyotrophic Lateral Sclerosis ALS-FTD Amyotrophic lateral sclerosis with frontotemporal dementia AP1 adaptor protein 1 AP2 adaptor protein 2 APOE Apolipoprotein E APP Amyloid Precursor Protein AZQ Jiaziquon BACE1 β-secretase 1 BCNU Carmustine BINAP 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl Br Bromine bs Broad Signal BSA Bovine Serum Albumin CaCl2 Calcium chloride CCNU Lomustine CD3OD Tetradeuteromethanol CHO Chinese hamster ovary Cl Chlorine CO2 Carbon Dioxide d double line dd Double line double line DCM Dichloromethane DIPEA N,N-Diisopropylethylamine DMF Dimethylformamide DMSO Dimethyl sulfoxide DMSO-d6 Hexadeuterodimethylsulfoxide EGF epidermal growth factor EtOH Ethanol F Fluorine FITC Fluorescein isothiocyanate FTD frontotemporal dementia FPA Fluorescence Polarization Binding Assay g / mg grams / milligrams GGA Golgi localized, γ-ear containing, ADP ribosylation factor 1 H NMR Proton Nuclear Magnetic Resonance h time H2 Hydrogen Gas HATU Hexafluorophosphate azabenzotriazole tetramethyluronium HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid His6-tag Hexahistidine tag H2O Water HCl Hydrochloric acid HOBt Hydroxybenzotriazole HPLC High Performance Liquid Chromatography Hz / MHz Hertz / Megahertz I Iodine I C 50 Half inhibitory concentration IC1-3 Intermediate compound 1-3 IMAC Immobilized Metal Ion Affinity Chromatography K2CO3 Potassium Carbonate LC Liquid Chromatography LCMS Liquid Chromatography Mass Spectrometry LDL Low Density Lipoprotein m multiplet M / mM / μM mole / millimole / micromolar M + Positively charged molecular mass related ions MeCN Acetonitrile MeOH Methanol MeCCNU Semustine ml / mL / μl / μL milliliter / microliter mm / μm millimeter / micrometer MMA Single limb muscular atrophy MNU N-nitroso-N-methylurea mol / mmol mole / millimol MSD Mass Detection MTBE Methyl tert-butyl ether N Nitrogen nm nanometer NaBH4 Sodium borohydride NaCl Sodium chloride NaHCO3 Sodium bicarbonate NH4Cl Ammonium chloride NOD Non-obese diabetes NTR3 Neurotensin receptor 3 NTRK1 Neurotrophic receptor tyrosine kinase 1 NTRK2 Neurotrophic receptor tyrosine kinase 2 NTRK3 Neurotrophic receptor tyrosine kinase 3 Oxygen O2 oxygen gas Pd / C Palladium Carbon Pd(OAc)2Palladium(II) Acetate p75NTR p75 neurotrophin receptor PBP progressive bulbar palsy PBS Phosphate Buffered Saline PCSK9 proprotein convertase subtilisin / kexin type 9 PLS Primary Lateral Sclerosis PMA progressive muscular atrophy PRGN Progranulin Pro-BDNF Pro-brain-derived neurotrophic factor Pro-NGF Pro-nerve growth factor P / S Penicillin / Streptomycin PTSA p-Toluenesulfonic acid RC1-3 Reference compound 1-3 RP-HPLC Reversed-phase high-performance liquid chromatography q quartet s Single line Sulfur SCID Severe Combined Immunodeficiency SEM-Cl 2-(trimethylsilyl)ethoxymethyl chloride SFC Supercritical Fluid Chromatography SI1-48 Sortilin inhibitor 1-48 SMA Spinal Muscular Atrophy sSORT1 secreted or soluble sortilin t triple line T3P n-Propanephosphonic anhydride TGN Trans-Golgi Network THF Tetrahydrofuran Ti(OEt)4 Titanium(IV) Ethoxide TLC Thin Layer Chromatography Trk Receptors Tyrosine Kinase Receptors UPLC Ultra High Performance Liquid Chromatography VLDL Very Low Density Lipoprotein Vps10p Vacuolar protein localization 10 protein
[0027] As used herein, the term "C1-C4 alkyl" includes methyl (-CH3), ethyl (-CH2CH3), propyl (-CH2CH2CH3), isopropyl (-CH(CH3)2), butyl (-CH2CH2CH2CH3), sec-butyl (-CH(CH3)(CH2CH3)), isobutyl (-CH2CH(CH3)2), and tert-butyl (-C(CH3)3).
[0028] As used herein, the term "C1-C4 alkoxy" includes methoxy (-OCH3), ethoxy (-OCH2CH3), propoxy (-OCH2CH2CH3), isopropoxy (-OCH(CH3)2), butoxy (-OCH2CH2CH2CH3), sec-butoxy (-OCH(CH3)(CH2CH3)), isobutoxy (-OCH2CH(CH3)2), and tert-butoxy (-OC(CH3)3).
[0029] As used herein, the term "halogen" includes fluorine (F), chlorine (Cl), bromine (Br), and iodine (I). In certain embodiments, as used herein, halogen includes F, Cl, and Br.
[0030] As used herein, the term "heteroatom" refers to a non-carbon atom replacing a carbon atom in a ring structure. According to the present invention, the heteroatom is selected from among nitrogen (N), oxygen (O) and sulfur (S). In a particular embodiment, the heteroatom is selected from among N and O. In a preferred embodiment, the heteroatom is N.
[0031] As used herein, the term "sortilin" may refer to full-length sortilin (also referred to as immature sortilin), including a signal peptide, a propeptide, a Vps10p domain, a 10CC domain, a transmembrane domain, and a large cytoplasmic tail, and having the amino acid sequence set forth in SEQ ID NO:1, or may refer to mature sortilin, or a naturally occurring fragment, homologue, or variant thereof, including a Vps10p domain, a 10CC domain, a transmembrane domain, and a large cytoplasmic tail, and having the amino acid sequence set forth in SEQ ID NO:2. As used herein, sortilin also encompasses secreted or soluble sortilin (sSORT1), which lacks the transmembrane domain and the large cytoplasmic tail. It is understood that sortilin can interact with progranulin (PGRN) and form a sortilin / PGRN complex.
[0032] As used herein, the term "Progranulin" or "PGRN" refers to a protein that is 593 amino acids long (SEQ ID NO: 3) and 68.5 kDa. Progranulin is the precursor protein of granulin. Cleavage of Progranulin produces a variety of small active cleavage products, called granulin A, granulin B, granulin C, etc.
[0033] As used herein, the term "sortilin antagonist" or "sortilin inhibitor" refers to a compound that interferes with, blocks, or otherwise attenuates the effect of PGRN binding to the sortilin molecule and preventing or at least inhibiting the formation of a complex between sortilin and PGRN. The compounds of formula I disclosed herein act as sortilin antagonists or inhibitors by binding to sortilin.
[0034] As used herein, the term "enantiomer" is one of two stereoisomers that are mirror images of each other and are non-superimposable (not identical). A single chiral atom or similar structural feature in a compound causes the compound to have two possible structures that are non-superimposable, each of which is the mirror image of the other. A sample of a compound is considered enantiopure, or enantiomerically pure, if it contains molecules with only one chirality within the limits of detection.
[0035] As used herein, the terms "racemate" or "racemic mixture" are a mixture of a chiral molecule having equal amounts of both enantiomers.
[0036] As used herein, the term "diastereomers" refers to stereoisomers that are not related as mirror images and are not enantiomers. Unlike enantiomers, which are mirror images of each other and are not superimposable, diastereomers are not mirror images. Diastereomers have two or more stereocenters and have different physical properties and reactivities.
[0037] As used herein, the term "pharmaceutical acceptable salts" includes therapeutically active non-toxic acid and base addition salt forms that the compounds of the present invention can form. Compounds that have basic properties can be converted to pharmaceutical acceptable acid addition salts by treating the base form with a suitable acid. Examples of acids include inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, and the like; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid, and the like. Compounds that have acidic properties can be converted to pharmaceutical acceptable base addition salts by treating the acid form with a suitable base. Suitable base addition salt forms are sodium, potassium, calcium salts and salts with pharma- ceutically acceptable amines, such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, for example, arginine and lysine. As used herein, the term "addition salts" also includes solvates, such as, for example, hydrates, alcoholates, and the like, which the compounds and their salts are able to form.
[0038] As used herein, the term "prodrug" refers to a biologically inactive derivative of a parent drug molecule that is activated by chemical or enzymatic transformation in the body, resulting in release of the active drug. In certain embodiments, the prodrug of a compound or sortilin inhibitor of the invention is a short chain ester-containing prodrug, preferably a C1-C4 ester prodrug of the compound or sortilin inhibitor.
[0039] An embodiment of the present invention is a compound of formula I [ka] (In the formula, A is a 5- or 6-membered aromatic ring, aromatic heterocycle, or heterocycle having 0-2 heteroatom(s) selected from N, O, and S, or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 heteroatom(s) selected from N, O, and S, and the aromatic ring, aromatic heterocycle, heterocyclic ring, or bicyclic ring A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; Y is absent, -O-, -OCH2-, -CH2-, -NR 3 - or -CH(NH2)-, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or 0-4 heteroatom(s) selected from among N, O and S, and the aromatic or heteroaromatic ring B is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; R 1 , R 2 , R 3 and R 4 are independently hydrogen or C1-C4 alkyl; Z is a halogen; R 5 is hydroxyl or C1-C4 alkoxy; or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
[0040] Certain embodiments relate to compounds of formula I above, or an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0041] Compounds of formula I have high affinity (IC in the nM range) 50value) to Sortilin. Thus, the compounds of formula I are suitable as Sortilin inhibitors. These Sortilin inhibitors of the present invention can block or at least significantly inhibit the binding of other ligands, such as PGRN, to Sortilin. Thus, Sortilin inhibitors can be used for the treatment of diseases, disorders, and conditions associated with the PGRN-Sortilin system, or the interaction between Sortilin and other ligands. Indeed, the Sortilin inhibitors of the present invention having an unsaturated aliphatic moiety (see the closed ring of formula II below) have a higher binding affinity to Sortilin compared to an optimized reference compound having a saturated aliphatic moiety (Bioorganic & Medicinal Chemistry Letters 2020 30:127403). [ka]
[0042] The sortilin inhibitors of the present invention further have biological effects as seen in the reduction of the formation of cancer stem cells (spheres). Such cancer stem cells are generally a population of treatment-resistant and aggressive cancer cells that may survive or evade conventional chemotherapy. Such cancer stem cells may disperse new tumors that are resistant to chemotherapy. Thus, the presence of cancer stem cells generally leads to cancer recurrence and metastasis, thereby leading to treatment failure. This means that there is a need to generally target such aggressive cancer cells. PGRN has previously been identified as the most effective of over 500 cytokines in inducing cancer stem cells and lung metastasis in breast cancer (Breast Cancer Research 2018 20:137). Furthermore, a subgroup of highly malignant cancer cells co-expresses PRGN and sortilin (BMC Cancer 2021 21:185). The sortilin inhibitors of the present invention can inhibit these effects.
[0043] Y is, as described above, absent, -O-, -OCH2-, -CH2-, -NR 3As used herein, -OCH- represents -OCH- and -CHO-. Thus, according to the present invention, Y is absent, -O-, -OCH-, -CHO-, -CH-, -NR 3 -, or -CH(NH2)-.
[0044] In one embodiment, A is a 5- or 6-membered aromatic ring, aromatic heterocycle or heterocycle having 0-2 heteroatom(s) selected from among N and O, or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 heteroatom(s) selected from among N and O. Thus, currently preferred heteroatoms for the aromatic heterocycle, heterocyclic ring or bicyclic ring A are nitrogen and / or oxygen atoms. In a particular embodiment, A is a 5- or 6-membered aromatic ring, aromatic heterocycle or heterocycle having 0-2 nitrogen atom(s), or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 nitrogen atoms. In this particular embodiment, the heteroatoms of the aromatic heterocycle, heterocyclic ring or bicyclic ring A are all nitrogen atoms.
[0045] In one embodiment, A is a 5- or 6-membered aromatic ring, heteroaromatic ring or heterocycle having 0-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N.
[0046] In one embodiment, A is a 5-membered aromatic heterocycle or heterocycle having 1-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In a particular embodiment, A is a 5-membered aromatic heterocycle having 1-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In another particular embodiment, A is a 5-membered heterocycle having 1-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N.
[0047] In another embodiment, A is a 6-membered aromatic ring, heteroaromatic ring or heterocycle having 0-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In a particular embodiment, A is a 6-membered aromatic ring. In another particular embodiment, A is a 6-membered heteroaromatic ring having 1-2 N as heteroatom(s). In a further particular embodiment, A is a 6-membered heterocycle having 1-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N.
[0048] In one embodiment, A is an 8-10 membered bicyclic heterocycle or aromatic heterocycle having 1 or 2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In one embodiment, A is a 9 membered bicyclic heterocycle or aromatic heterocycle having 1 or 2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In a particular embodiment, A is a 9 membered bicyclic heterocycle having 1 or 2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. In another particular embodiment, A is a 9 membered aromatic heterocycle having 1 or 2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N.
[0049] In the above embodiment, ring A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0050] In one embodiment, A is a 5- or 6-membered aromatic ring, heteroaromatic ring or heterocyclic ring having 0-2 heteroatom(s) selected from among N and O, preferably N, or a 9-membered bicyclic heterocycle having 1 or 2 heteroatom(s) selected from among N and O, preferably N. In this embodiment, the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0051] In one embodiment, any C1-C4 alkyl substituents of the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A are preferably independently selected from the group consisting of methyl, isobutyl and tert-butyl.
[0052] In one embodiment, R 1 and R 2 is independently selected from the group consisting of hydrogen, methyl and ethyl. In a preferred embodiment, R 1 and R 2 is independently selected from the group consisting of hydrogen and methyl. In particularly preferred embodiments, R 1 and R 2 are both methyl.
[0053] In a preferred embodiment, the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally substituted with one or more substituents independently selected from the group consisting of -CH3, -CH2CH(CH3)2, -C(CH3)3, -N(CH3)2, -C(O)CZ3, halogen, and =O.
[0054] In one embodiment, Z is selected from the group consisting of F, Cl and Br. In certain embodiments, Z is F or Cl. In preferred embodiments, Z is F. In such preferred embodiments, the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally substituted with one or more substituents independently selected from the group consisting of -CH3, -CH2CH(CH3)2, -C(CH3)3, -N(CH3)2, -C(O)CF3, and halogen.
[0055] In one embodiment, the halogen substituents of ring A are preferably selected from the group consisting of F, Cl and Br. In certain embodiments, the halogen substituents of ring A are Cl or Br. In certain such embodiments, the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally substituted with one or more substituents independently selected from the group consisting of -CH3, -CH2CH(CH3)2, -C(CH3)3, -N(CH3)2, -C(O)CZ3, -Cl and -Br.
[0056] In currently preferred embodiments, the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally substituted with one or more substituents independently selected from the group consisting of -CH3, -CH2CH(CH3)2, -C(CH3)3, -N(CH3)2, -C(O)CF3, -Cl, and -Br.
[0057] As described above, Y is absent, -O-, -OCH2-, -CH2-, -NR 3 -, or -CH(NH2)-. When not present, Y represents a direct bond or a bond between the aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A and, when present, the aromatic ring or heteroaromatic ring B.
[0058] In one embodiment, R 3 is selected from the group consisting of hydrogen, methyl and ethyl. In certain embodiments, R 3 is selected from the group consisting of hydrogen and methyl. In certain preferred embodiments, R 3 is hydrogen.
[0059] In certain embodiments, Y is absent, -O-, -OCH2-, -CH2-, -NH- or -CH(NH2)-, or preferably, Y is absent, -O-, -OCH2-, -NH- or -CH(NH2)-. In another particular embodiment, Y is absent or O. In a preferred embodiment, Y is absent. Thus, in such an embodiment, the compound has the following formula III: [ka] (In the formula, A is a 5- or 6-membered aromatic ring, aromatic heterocycle, or heterocycle having 0-2 heteroatom(s) selected from N, O, and S, or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 heteroatom(s) selected from N, O, and S, and the aromatic ring, aromatic heterocycle, heterocyclic ring, or bicyclic ring A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or zero to four heteroatom(s) selected from among N, O and S, and the aromatic or heteroaromatic ring B is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; R 1 , R 2 , R 3 and R 4 are independently hydrogen or C1-C4 alkyl; Z is a halogen; R 5 is hydroxyl or C1-C4 alkoxy; or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0060] In one embodiment, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or zero to four heteroatom(s) selected from among N and O. Thus, currently preferred heteroatoms for the aromatic heterocycle B are nitrogen and / or oxygen atoms. In certain embodiments, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or zero to four nitrogen atom(s). In this particular embodiment, all heteroatoms in the aromatic heterocycle B are nitrogen atoms. In these embodiments, the aromatic or heteroaromatic ring B is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0061] In one embodiment, B is a 5-membered aromatic heterocycle having 1-4 heteroatom(s) that are absent, selected from among N, O and S, preferably selected from among N and O, more preferably N, or a 6-membered aromatic or heteroaromatic ring containing 1-4 N as heteroatom(s). In this embodiment, the aromatic or heteroaromatic ring B is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0062] In one embodiment, B is absent.
[0063] In another embodiment, B is a 6-membered aromatic ring. The aromatic ring B is optionally selected from the group consisting of C1-C4 alkyl, -NR 1 R2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0064] In a further embodiment, B is a 5- or 6-membered aromatic heterocycle having 1-4 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. The aromatic heterocycle B is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen, and =O.
[0065] In one embodiment, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or 0-4 heteroatom(s) selected from among N, O, and S. The aromatic or heteroaromatic ring B is optionally selected from -OR 4 and ═O. In one embodiment, B is a 5- or 6-membered aromatic or heteroaromatic ring having zero to four heteroatom(s) that are absent or selected from among N and O, preferably N. The aromatic or heteroaromatic ring B is optionally substituted with one or more substituents independently selected from the group consisting of -OR 4 and ═O.
[0066] In one embodiment, R 4 is selected from the group consisting of hydrogen, methyl and ethyl. Thus, in such embodiments, the substituent -OR 4 is selected from the group consisting of hydroxyl (-OH), methoxy (-OCH3), and ethoxy (-OCH2CH3). 4 is selected from the group consisting of hydrogen and methyl.
[0067] In certain embodiments, the aromatic or heteroaromatic ring B is optionally substituted with one or more substituents independently selected from the group consisting of hydroxyl, methoxy, or =O.
[0068] As mentioned above, R 5 is hydroxyl or C1-C4 alkoxy. In certain embodiments, R 5 is hydroxyl or C1-C2 alkoxy, i.e., R 5 is selected from the group consisting of hydroxyl, methoxy and ethoxy. In certain preferred embodiments, R 5 is hydroxyl.
[0069] In one embodiment, A is a 5- or 6-membered aromatic ring, heteroaromatic ring or heterocycle having 0-2 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. The aromatic ring, heteroaromatic ring or heterocycle A is optionally selected from C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4 , halogen and =O, preferably independently selected from the group consisting of methyl, isopropyl, isobutyl, -N(CH3)2, -N(CH2CH3)2, -C(O)CF3, Cl and Br. Substituted with one or more substituents. In this embodiment, Y is absent, -O-, -OCH2-, -CH2-, -NH-, or -CH(NH2)-. In this embodiment, B is absent, a 6-membered aromatic ring or a 5- or 6-membered aromatic heterocycle having 0-4 heteroatom(s) selected from among N, O and S, preferably selected from among N and O, more preferably N. The aromatic ring or aromatic heterocycle B is optionally selected from the group consisting of C1-C4 alkyl, -NR 1 R 2 , -C(O)CZ3, -OR 4, halogen, and =O, preferably hydroxyl, methoxy, and =O. In this embodiment, R 5 is hydroxyl or C1-C4 alkoxy, preferably hydroxyl or C1-C2 alkoxy, more preferably hydroxyl.
[0070] Currently preferred compounds of formula I include the following compounds: [ka] (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (Sortilin inhibitor 1 (SI1)) [ka] (E)-5,5-Dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid (SI2) [ka] (E)-5,5-Dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI3) [ka] (E)-5,5-Dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI4) [ka] (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5) [ka] (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6) [ka] (E)-5,5-Dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7) [ka] (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8) [ka] (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI9) [ka] (E)-5,5-Dimethyl-2-[4-(2-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid (SI10) [ka] (E)-5,5-Dimethyl-2-[4-(4-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid (SI11) [ka] (E)-5,5-Dimethyl-2-[4-(3-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid (SI12) [ka] (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid (SI13) [ka] (E)-2-(3-isobutyl-5-isoxazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI14) [ka] (E)-5,5-Dimethyl-2-[1-(4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid (SI15) [ka] (E)-5,5-Dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid (SI16) [ka] (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI17) [ka] (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI18) [ka] (E)-2-[2-(dimethylamino)-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI19) [ka] (E)-2-[2-(dimethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI20) [ka] (E)-2-[2-(diethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI21) [ka] (E)-5,5-Dimethyl-2-[p-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI22) [ka] (E)-5,5-Dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI23) [ka] (E)-5,5-Dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI24) [ka] (E)-5,5-Dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid (SI25) [ka] (E)-5,5-Dimethyl-2-[m-(1H-tetrazol-1-yl)benzoylamino]-3-hexenoic acid (SI26) [ka] (E)-5,5-Dimethyl-2-[2-(4H-1,2,4-triazol-4-yl)isonicotinoylamino]-3-hexenoic acid (SI27) [ka] (E)-2-(4-Bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI28) [ka] (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI29) [ka] (E)-2-(4,5-dichloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI30) [ka] (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31) [ka] (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32) [ka] (E)-2-(5-isopropyl-3-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI33) [ka] (E)-5,5-Dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (SI34) [ka] (E)-5,5-Dimethyl-2-(5-phenoxynicotinoylamino)-3-hexenoic acid (SI35) [ka] (E)-5,5-Dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid (SI36) [ka] (E)-5,5-Dimethyl-2-[p-(2-pyridyloxy)benzoylamino]-3-hexenoic acid (SI37) [ka] (E)-5,5-Dimethyl-2-[m-(2-pyridyloxy)benzoylamino]-3-hexenoic acid (SI38) [ka] (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI39) [ka] (E)-5,5-Dimethyl-2-[p-(6-methyl-2-pyrazinyloxy)benzoylamino]-3-hexenoic acid (SI40) [ka] (E)-5,5-Dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid (SI41) [ka] (E)-2-[m-(5-chloro-2-pyridyloxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI42) [ka] (E)-2-[6-(p-bromophenoxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI43) [ka] (E)-5,5-Dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid (SI44) [ka] (E)-2-{6-[p-(tert-butyl)phenoxy]nicotinoylamino}-5,5-dimethyl-3-hexenoic acid (SI45) [ka] (E)-2-[2-(p-Cumenyloxy)isonicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI46) [ka] (E)-5,5-Dimethyl-2-(5-phenoxy-2-pyrazinylcarbonylamino)-3-hexenoic acid (SI47) [ka] (E)-5,5-Dimethyl-2-[p-(5-methyl-2-pyridinyloxy)benzoylamino]-3-hexenoic acid (SI48) [ka] (E)-2-(2-Isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI49) [ka] (E)-5,5-Dimethyl-2-[6-(4H-1,2,4-triazol-4-yl)-2-pyridylcarbonylamino]-3-hexenoic acid (SI50) [ka] (E)-5,5-Dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51) [ka] (E)-5,5-Dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52) [ka] (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI53) [ka] (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI54) [ka] (E)-5,5-Dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid (SI55) [ka] (E)-2-(1-Ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI56) [ka] (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI57) [ka] (E)-2-(3-Isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI58) [ka] (E)-5,5-Dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid (SI59) [ka] (E)-2-[3-(3,4-dichlorophenyl)-1-methyl-5-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI60) [ka] (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI61) [ka] (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid (SI62) [ka] (E)-2-(2-benzyl-4-methyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI63) [ka] (E)-5,5-Dimethyl-2-[4-methyl-2-(p-toluidino)-5-pyrimidinylcarbonylamino]-3-hexenoic acid (SI64) [ka] (E)-2-[2-(p-chlorophenylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI65) [ka] (E)-2-[6-(p-chlorophenoxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI66) [ka] (E)-5,5-Dimethyl-2-[6-(p-tolyloxy)nicotinoylamino]-3-hexenoic acid (SI67) [ka] (E)-2-(6-benzylnicotinoylamino)-5,5-dimethyl-3-hexenoic acid (SI68) [ka] (E)-2-(p-benzylbenzoylamino)-5,5-dimethyl-3-hexenoic acid (SI69) [ka] (E)-5,5-Dimethyl-2-(p-phenoxybenzoylamino)-3-hexenoic acid (SI70) [ka] (E)-5,5-Dimethyl-2-(6-phenylnicotinoylamino)-3-hexenoic acid (SI71) [ka] (E)-5,5-Dimethyl-2-(2-phenylisonicotinoylamino)-3-hexenoic acid (SI72) [ka] (E)-5,5-Dimethyl-2-[6-(2-thienyloxy)nicotinoylamino]-3-hexenoic acid (SI73) [ka] (E)-2-(5-chloro-1-benzothiophen-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI74) [ka] (E)-2-(5-chloro-2-indolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI75) [ka] (E)-5,5-Dimethyl-2-(1-thia-5-aza-2-indenylcarbonylamino)-3-hexenoic acid (SI76) [ka] (E)-2-(2-chloro-1-benzothiophen-6-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI77) [ka] (E)-2-(2-chloro-6-indolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI78) [ka] (E)-2-(4-chloro-1,3-thiazol-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI79) [ka] (E)-2-(4,5-dichloro-1,3-thiazol-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI80) [ka] (E)-2-(3-chloro-5-isothiazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI81) [ka] (E)-2-(3,4-dichloro-5-isothiazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI82) [ka] (E)-5,5-Dimethyl-2-[m-(3-pyridyl)benzoylamino]-3-hexenoic acid (SI83) [ka] (E)-2-[m-(6-chloro-2-methyl-3-pyridyl)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI84) or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0071] In certain embodiments, preferred compounds of formula I include the following compounds: (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), (E)-5,5-Dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid (SI2), (E)-5,5-Dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI3), (E)-5,5-Dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI4), (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6), (E)-5,5-Dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7), (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8), (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI9), (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid (SI13), (E)-5,5-Dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid (SI16), (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI17), (E)-5,5-Dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI23), (E)-5,5-Dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI24), (E)-5,5-Dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid (SI25), (E)-2-(4-Bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI28), (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI29), (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31), (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32), (E)-5,5-Dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (SI34), (E)-5,5-Dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid (SI36), (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI39), (E)-5,5-Dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid (SI41), (E)-5,5-Dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid (SI44), (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI49), (E)-5,5-Dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51), (E)-5,5-Dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52), (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI53), (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI54), (E)-5,5-Dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid (SI55), (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI56), (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI57), (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI58), (E)-5,5-Dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid (SI59), (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI61), (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid (SI62), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0072] In another embodiment, preferred compounds of formula I include the following compounds: (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), (E)-5,5-Dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid (SI2), (E)-5,5-Dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI3), (E)-5,5-Dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI4), (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6), (E)-5,5-Dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7), (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8), (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI9), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0073] In certain preferred embodiments, preferred compounds of formula I include the following compounds: (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6), (E)-5,5-Dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7), (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8), (E)-5,5-Dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI23), (E)-5,5-Dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI24), (E)-5,5-Dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid (SI25), (E)-2-(4-Bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI28), (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI29), (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31), (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32), (E)-5,5-Dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (SI34), (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI39), (E)-5,5-Dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid (SI44), (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI49), (E)-5,5-Dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51), (E)-5,5-Dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52), (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI53), (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI54), (E)-5,5-Dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid (SI55), (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI56), (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI57), (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI58), (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI61), (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid (SI62), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0074] In another preferred specific embodiment, preferred compounds of formula I include the following compounds: (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6), (E)-5,5-Dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7), (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0075] In certain more preferred embodiments, preferred compounds of formula I include the following compounds: (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), (E)-5,5-Dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), (E)-5,5-Dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6), (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8), (E)-5,5-Dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI24), (E)-5,5-Dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid (SI25), (E)-2-(4-Bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI28), (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31), (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32), (E)-5,5-Dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (SI34), (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI39), (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI49), (E)-5,5-Dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51), (E)-5,5-Dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52), (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI57), (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid (SI62), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, for example, an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0076] A currently preferred compound of the invention is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0077] Another currently preferred compound of the invention is (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0078] A further currently preferred compound of the invention is (E)-5,5-dimethyl-2-[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid (SI25), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0079] Another preferred compound of the present invention is (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0080] A further preferred compound of the invention is (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0081] Yet another preferred compound of the invention is (E)-2-[6-(benzoyloxy)nicotinoylamino]5,5-dimethyl-3-hexenoic acid (SI39), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0082] Another preferred compound of the invention is (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0083] A further preferred compound of the invention is (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0084] Yet another preferred compound of the invention is (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid (SI62), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof, such as an enantiomer thereof, a diastereomer thereof, a racemate thereof, or a pharma- ceutically acceptable salt thereof.
[0085] The compounds of the present invention can be prepared from intermediates synthesized as disclosed in steps 1-3 of Example 1, as further described in Examples 1-37 below. The present invention also encompasses such intermediates, i.e., compounds D, E and F of Example 1, and compositions thereof. Thus, the present invention also relates to intermediates for preparing compounds of formula I. The intermediates are (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexenoic acid (intermediate compound 1, IC1), Ethyl (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexanoate (IC2), and ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (IC3).
[0086] In one embodiment, the intermediate is (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexenoic acid (IC1). IC1 can be prepared by adding 2-tert-butyl-E-vinylboronic acid to 4-methoxybenzylamine in dry dichloromethane, followed by the addition of glyoxylic acid monohydrate to give IC1 (Step 1 of Example 1).
[0087] In another embodiment, the intermediate is ethyl (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexanoate (IC2), which can be prepared by adding sulfuric acid to a suspension of IC1 in ethanol to give IC2 (Step 2 of Example 1).
[0088] In a preferred embodiment, the intermediate is ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (IC3), which can be prepared by adding a pre-dissolved solution of cerium diammonium nitrate in water to a solution of IC2 in acetonitrile to give IC3 (Step 3 of Example 1).
[0089] The sortilin inhibitors of the present invention can bind to sortilin with high affinity (A-K, O-S in FIG. 1, Table 1). In fact, the sortilin inhibitors of the present invention had higher binding affinity than the optimized reference compounds (RC1 and RC2 of L and M in FIG. 1, and Table 1) that have saturated aliphatic moieties rather than unsaturated aliphatic moieties (see closed ring in formula II). The sortilin inhibitors of the present invention can further block or at least significantly inhibit the binding of other ligands, such as PGRN, to sortilin. This means that the sortilin inhibitors of the present invention can be used to treat diseases, disorders and conditions associated with or characterized by the binding of such ligands to sortilin, and interruption or at least inhibition of the binding of such ligands to sortilin is beneficial to patients in terms of treating the disease, disorder or condition.
[0090] Therefore, the sortilin inhibitors of the present invention can be used as medicines.
[0091] Sortilin and its multiple ligands, through various interactions with proteins such as PGRN, have been shown to be involved in various diseases, disorders and conditions such as frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), ALS-FTD phenotype, Alzheimer's disease, Parkinson's disease, depression, neuropsychiatric disorders, vascular dementia, epileptic seizures, retinal dystrophies, age-related macular degeneration, glaucoma, traumatic brain injury, aging, epileptic seizures, wound healing, stroke, arthritis, atherosclerotic vascular diseases, dermatological related diseases, and autoimmune diseases (WO2009 / 140972, WO2014 / 114779, WO2016 / 164637, Bioorganic & Medicinal Chemistry Letters2020 30:127403).
[0092] Therefore, the sortilin inhibitors of the present invention can be used to prevent or treat neurodegenerative diseases, psychiatric diseases, motor neuron diseases, peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, cardiovascular diseases, dermatological related diseases or autoimmune diseases.
[0093] Illustrative, but non-limiting examples of neurodegenerative diseases include FTD, ALS, ALS-FTD phenotype, stroke, traumatic brain injury, retinal degeneration, light-induced photoreceptor degeneration, Alzheimer's disease, and Parkinson's disease.
[0094] Illustrative, but non-limiting, examples of psychiatric disorders include depression, neuropsychiatric disorders, epilepsy, and bipolar disorder.
[0095] Illustrative, but non-limiting examples of motor neuron diseases include ALS, progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), spinal muscular atrophy (SMA), and monomuscular muscular atrophy (MMA).
[0096] Illustrative, but non-limiting, examples of peripheral neuropathy include diabetic neuropathy.
[0097] Illustrative, but non-limiting examples of pain include acute pain, chronic pain, neuropathic pain, back pain, post-operative pain, and inflammatory pain.
[0098] Illustrative, but non-limiting examples of neuroinflammatory diseases include rheumatoid arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis.
[0099] Illustrative, but non-limiting examples of hyperlipidemia include hyperlipoproteinemia type I, such as Burger-Gruetz syndrome, primary hyperlipoproteinemia, or familial hyperchylomicronemia; hyperlipoproteinemia type Na, such as polygenic hypercholesterolemia or familial hypercholesterolemia; hyperlipoproteinemia type Nb, such as combined hyperlipidemia; hyperlipoproteinemia type III, such as familial dysbetalipoproteinemia; hyperlipoproteinemia type IV, such as endogenous hyperlipidemia; and hyperlipoproteinemia type V, such as familial hypertriglyceridemia. Other examples of diseases or disorders caused by or having a component of hyperlipidemia include aneurysm, angina pectoris, atherosclerosis, cerebrovascular disorders or diseases, congenital heart disease, congestive heart failure, coronary artery disease, dilated cardiomyopathy, diastolic dysfunction, endocarditis, hypercholesterolemia, hypertension, hypertrophic cardiomyopathy, mitral valve prolapse, myocardial infarction, and venous thromboembolism.
[0100] Illustrative, but non-limiting examples of dermatologically related diseases include psoriasis, dermal fibrosis, and cutaneous keratosis.
[0101] Illustrative, but non-limiting examples of autoimmune diseases include psoriasis, rheumatoid arthritis, diabetes, and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
[0102] The PGRN-sortilin system is also important for cancer. More specifically, aggressive cancer cells co-express PGRN and sortilin, which leads to sphere (cancer stem cell) formation and metastasis. Therefore, by blocking or at least inhibiting the interaction between PGRN and sortilin, sphere formation is prevented or at least significantly inhibited (Example 42) and metastasis may also be reduced (Breast Cancer Research 2018 20:137). High PGRN levels have been found in various types of cancer, including but not limited to breast cancer, bladder cancer, lymphoma, cholangiocarcinoma, and pancreatic cancer.
[0103] Thus, the sortilin inhibitors of the present invention can be used to prevent or treat cancer.
[0104] In one embodiment, the cancer is selected from the group consisting of breast cancer, bladder cancer, lymphoma, biliary tract cancer, colon cancer, melanoma, and pancreatic cancer. In a preferred embodiment, the cancer is selected from the group consisting of breast cancer, colon cancer, and melanoma, more preferably breast cancer.
[0105] In certain embodiments, the sortilin inhibitors of the present invention are used to prevent or treat metastasis. Further uses of the sortilin inhibitors of the present invention include preventing or treating sphere formation, and inhibiting the formation and / or migration of cancer stem cells.
[0106] The present invention also relates to a pharmaceutical composition comprising a sortilin inhibitor according to the present invention and at least one pharma- ceutically acceptable excipient, carrier or diluent.
[0107] As used herein, a pharma- ceutically acceptable excipient, carrier, or diluent encompasses a variety of pharma- ceutically acceptable additives, including, but not limited to, excipients, carriers, diluents, adjuvants, colorants, flavorings, preservatives, and the like, that one of skill in the art would consider for use in formulating the sortilin inhibitors of the present invention to produce a pharmaceutical composition.
[0108] Pharmaceutically acceptable excipients, carriers, or diluents include, but are not limited to, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine; lubricants such as silica, talc, stearic acid (including its salts), and polyethylene glycol; binders such as magnesium and aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone; disintegrating agents such as starch, agar, alginic acid, sodium alginate; absorbents; dyes; flavorings; sweeteners; polypropylene glycol; and liquid vehicles such as water, saline, aqueous dextrose, glycerol, ethanol, and oils.
[0109] The at least one excipient, carrier and / or diluent is pharma- ceutically acceptable in that it is compatible with the sortilin inhibitor of the present invention (compound of formula I) and any other ingredients of the pharmaceutical composition, and is not harmful to a subject when the pharmaceutical composition is administered to a subject. For example, the pharmaceutical composition preferably does not contain any substance that may cause an adverse reaction, such as an allergic reaction, when administered to a subject.
[0110] In one embodiment, the pharmaceutical composition comprises 1-99% by weight of at least one pharma- ceutically acceptable excipient, carrier and / or diluent and 1-99% by weight of at least one sortilin inhibitor of the present invention.
[0111] The pharmaceutical composition can contain a single sortilin inhibitor according to the invention or multiple sortilin inhibitors according to the invention, ie, a mixture of two or more different sortilin inhibitors.
[0112] In one embodiment, a pharmaceutical composition may include, in addition to one or more sortilin inhibitors of the present invention, at least one second active agent.
[0113] The at least one second active agent can be an active agent that is traditionally used to treat a disease, disorder, or condition associated with Sortilin activity and ligand binding, such as binding of PGRN to Sortilin. Thus, the at least one active agent can be an active agent used to prevent or treat a neurodegenerative disease, a psychiatric disease, a motor neuron disease, a peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, a cardiovascular disease, a dermatological-related disease, or an autoimmune disease.
[0114] In another embodiment, at least one second active agent is a cytostatic agent or other anticancer drug.Non-limiting examples of such cytostatic agents that can be used in the pharmaceutical composition include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, busulfan, N-nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), semustine (MeCCNU), fotemustine, streptozotocin, dacarbazine, mitozolomide, temozolomide, thiocarbamate ... Alkylating agents such as tepa, mitomycin, diaziquone (AZQ), cisplatin, carboplatin and oxaliplatin; antimetabolites such as methotrexate, pemetrexed, fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, clofarabine, pentostatin, thioguanine and mercaptopurine; Catharanthus anti-microtubule agents such as the vinca alkaloids from Roseus, vincristine, vinblastine, vinorelbine, vindesine, vinflunine, paclitaxel, docetaxel, podophyllotoxin, etoposide, and teniposide; topoisomerase inhibitors such as irinotecan, topotecan, camptothecin, etoposide, doxorubicin, mitoxantrone, teniposide, novobiocin, merbarone, and aclarubicin; and cytotoxic antibiotics such as doxorubicin, daunorubicin, epirubicin, idarubicin, pirarubicin, aclarubicin, mitoxantrone, actinomycin, bleomycin, mitomycin C, and actinomycin.
[0115] In certain embodiments, the at least one second active agent is progranulin.
[0116] A pharmaceutical composition containing multiple active agents may be formulated in a unit dosage form containing the multiple active agents, or may be formulated as separate dosage forms containing each active agent, in which case the multiple separate dosage forms may be administered substantially simultaneously or separately, e.g., sequentially.
[0117] The pharmaceutical compositions may be solid pharmaceutical compositions such as tablets, pills, powders or granules, semi-solid pharmaceutical compositions such as suppositories, or liquid pharmaceutical compositions such as soft capsules or injectable solutions.
[0118] The sortilin inhibitors of the present invention, particularly the pharmaceutical compositions comprising at least one sortilin inhibitor of the present invention, can be administered to a subject using various administration routes.Exemplary but non-limiting examples of such administration routes include oral, intravenous, topical, intraperitoneal, nasal, buccal, sublingual or subcutaneous administration, or administration via the airway.The pharmaceutical composition of the present invention can be formulated based on a specific administration route.Exemplary but non-limiting examples of the formulation of the pharmaceutical composition include tablets, capsules, powders, nanoparticles, crystals, amorphous substances, solutions, transdermal patches, (transdermal) creams or suppositories.
[0119] The present invention is also a method for treating a disease, disorder or condition selected from the group consisting of a neurodegenerative disease, a psychiatric disease, a motor neuron disease, a peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, a cardiovascular disease, a dermatological-related disease, an autoimmune disease, and cancer. The method comprises administering a therapeutically effective amount of a sortilin inhibitor of the present invention or a pharmaceutical composition of the present invention to a subject in need thereof.
[0120] As used herein, "treatment" or "treating" refers to the management and care of a subject with the aim of combating a disease, disorder or condition. The term is intended to include the full range of treatments for a given disease, disorder or condition from which a subject suffers, such as administration of a sortilin inhibitor or pharmaceutical composition of the present invention to alleviate symptoms or complications, slow the progression of the disease, disorder or condition, relieve or alleviate symptoms and complications, and / or cure or eliminate the disease, disorder or condition, as well as to prevent the disease, disorder or condition. In such a case, prevention should be understood as the management and care of a subject with the aim of combating a disease, disorder or condition, and includes administration of a sortilin inhibitor or pharmaceutical composition of the present invention to prevent the onset of symptoms or complications. Treatment can be carried out in either an acute or chronic phase.
[0121] As used herein, a "therapeutically effective amount" of a sortilin inhibitor or pharmaceutical composition of the present invention means an amount sufficient to cure, inhibit, reduce or partially arrest the clinical symptoms of a given disease, disorder or condition and its complications. An appropriate amount to achieve this is defined as a "therapeutically effective amount". The effective amount for each purpose will vary depending on the severity of the disease, disorder or condition, and on the subject's parameters such as the subject's weight, sex, age, general health, etc. It will be understood that determining the appropriate dosage can be accomplished using routine experimentation by constructing a matrix of values and testing different points within the matrix, all of which are within the ordinary skill of a trained physician or veterinarian.
[0122] A related aspect of the present invention defines the use of a sortilin inhibitor of the present invention for the manufacture of a medicament for treating a disease, disorder or condition selected from the group consisting of a neurodegenerative disease, a psychiatric disease, a motor neuron disease, a peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, a cardiovascular disease, a dermatologically related disease, an autoimmune disease, and cancer.
[0123] The subject treated with the sortilin inhibitor or pharmaceutical composition of the present invention is preferably a human subject. However, the present invention can be used for veterinary purposes by administering the sortilin inhibitor or pharmaceutical composition of the present invention to a non-human mammal. Illustrative but non-limiting examples of such non-human mammals include dogs, cats, cows, horses, sheep, goats, pigs, rats, mice, rabbits and guinea pigs. EXAMPLES
[0124] The following analytical and chromatographic equipment was used in the synthesis of the compounds of the present invention, as described below: Liquid chromatography mass spectrometry (LCMS)-1: Agilent LC / MSD Trap XCT Plus; LCMS-2: Agilent 6130 single quadrupole LCMSC08UPD665M; Ultra-Performance Liquid Chromatography (UPLC) MS: Waters ACQUITY UPLCMS SQD Proton nuclear magnetic resonance ( 1 H-NMR):Bruker Avance III HD(400MHz) High performance liquid chromatography (HPLC): Shimadzu / Prominence and Prominence-I series (L2145610638AE) HPLC column: Agilent Zorbax SB-CN250×4.6mm 5μm SFC chiral purification columns: Chiralpak IG 250 x 30 mm (preparative), 250 x 10 mm (semi-preparative), and Chiralpak IG 250 x 4.6 mm (analytical) CombiFlash Rf, Model: RF+UV, Serial: Teledyne Isco 216C08126
[0125] Example 1 - Synthesis of (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1) Step 1: Synthesis of (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexenoic acid (D) [ka] 2-tert-Butyl-E-vinylboronic acid (A) (1.86 g, 0.014 mol) was added to a stirred solution of 4-methoxybenzylamine (C) (2 g, 0.014 mol) in dry dichloromethane (DCM, 22 mol, 0.33 M with respect to the amine) at 25-30° C., followed by glyoxylic acid monohydrate (B) (1.34 g, 0.014 mol). The resulting reaction mixture was stirred at 25-30° C. for 24 h under an argon atmosphere. The progress of the reaction was monitored by thin layer chromatography (TLC).
[0126] After completion of the reaction, the reaction mixture was filtered off and the solid obtained was washed with DCM and dried at 40° C. to obtain the expected product (D) as a white solid.
[0127] Yield: 1.78g, (44.5%) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),3.78(3H,s),3.86-3.89(1H,m),4.0-4.1(2H,m),5.38-5.45(1 H,m),5.98(1H,d,J=16.0Hz),6.95(2H,dd,J1=2.4Hz,J2=6.8Hz),7.35(2H,dd,J1=2.0Hz,J2=6.4Hz); LCMS: 278.2 [M+H] +
[0128] Step 2: Synthesis of ethyl (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexanoate (E) [ka] Sulfuric acid (3.4 ml) was added dropwise to a stirred suspension of compound D (1.7 g, 0.006 mol) in ethanol (34 ml) at 0-5° C. The resulting reaction mixture was stirred at 90° C. for 24 hours. The progress of the reaction was monitored by TLC.
[0129] After completion of the reaction, the reaction mixture was evaporated at 40° C. to remove ethanol. The remaining mixture was basified to pH 7-8 using saturated NaHCO3 solution and the product was extracted into ethyl acetate (3×20 ml). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure at 40° C. to give the crude product (E) as a light brown oil. The crude product was used directly in the next reaction without purification.
[0130] Yield: 1.3 g (crude product) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),1.22(3H,t,J=7.2Hz),3.60-3.63(2H,m),3.69-3.71(1H,m),3.75( 3H,s),4.15(2H,q,J=7.2Hz),5.27-5.33(1H,m),5.71-5.77(1H,m),6.83-6.87(2H,m),7.17-7.21(2H,m); LCMS: 306.3 [M+H] +
[0131] Step 3: Synthesis of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (F) [ka] A pre-dissolved solution of cerium ammonium nitrate (14.0 g, 0.0255 mol) in water (15.6 ml) was added dropwise over 15 min to a stirred solution of compound E (1.3 g, 0.0042 mol) in acetonitrile (15.6 ml) at 0-5° C. The resulting reaction mixture was stirred at 25-30° C. for 18 h. The progress of the reaction was monitored by TLC.
[0132] After completion of the reaction, the reaction mixture was evaporated at 25° C. to remove acetonitrile and basified to pH 7-8 using saturated NaHCO3 solution. The thick suspension was filtered through a celite bed, the celite bed was washed with ethyl acetate and the resulting layers were separated. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure at 35° C. to obtain the crude product. The crude product was purified by CombiFlash® using methanol / DCM as eluent to obtain the expected product (F) as a light brown oil.
[0133] Yield: 255mg, (32.3%) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),1.25(3H,t,J=7.2Hz),3.93-3.95(1H,m),4.18(2H,q,J=7.2Hz),5.40-5.46(1H,m),5.77-5.82(1H,m); LCMS: 186.1 [M+H] +
[0134] Step 4: Synthesis of ethyl (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexanoate (H) [ka] 2-(Dimethylamino)-4-methylpyrimidine-5-carboxylic acid (G) (244.4 mg, 1.3493 mmol) was added to a stirred solution of compound F (250 mg, 1.3493 mmol) in dimethylformamide (DMF, 6.25 ml) at 25-30 °C, followed by the addition of N,N-diisopropylethylamine (DIPEA, 0.94 mL, 5.3972 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (2.57 mL, 4.0479 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0135] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and then the product was extracted into ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give the pure product (H) as a light brown thick oil.
[0136] Yield: 62mg, (13.2%) 1 H-NMR-CD3OD(400MHz):δ:1.02(9H,s),1.25(3H,t,J=7.2Hz),2.44(3H,s),3.18(6H,s),4. 19(2H,t,J=7.2Hz),4.94-4.92(1H,m),5.47-5.54(1H,m),5.87-5.91(1H,m),8.33(1H,s); LCMS: 349.3 [M+H] +
[0137] Step 5: Synthesis of (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (I) [ka] Lithium hydroxide monohydrate (33.11 mg, 0.7892 mmol) was added to a stirred solution of compound H (55 mg, 0.1578 mmol) in tetrahydrofuran (THF) / methanol / water (1.65 ml, 1:1:1, 0.55 ml each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0138] After 18 h, the reaction mixture was concentrated and the remaining residue was dissolved in water and washed with ethyl acetate, the aqueous layer was acidified to pH approx. 2-3 using 1.5 N HCl, and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over sodium sulfate, and concentrated at 35° C. to give the crude product. The crude solid was triturated with hexane and dried at 40° C. to give the pure final product (I) as an off-white solid.
[0139] Yield: 37mg, (73.2%) 1 H-NMR-DMSO-d6(400MHz):δ:0.98(9H,s),2.40(3H,s),3.13(6H,s),4.78-4.82(1H,m),5 .45-5.50(1H,m),5.80-5.84(1H,m),8.37(1H,s),8.57(1H,d,J=7.2Hz),12.59(1H,bs); LCMS: 321.3 [M+H] + ; HPLC purity: 98.6%
[0140] Separation of the enantiomers of (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI1) (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (12 mg, 34 mmol) synthesized in Example 1 was dissolved in methanol (7 mL) and purified by preparative supercritical fluid chromatography (SFC) using a CHIRALPAK-ID column (250 mm x 10 mm, 5 μM) eluted with methanol, 15% CO2 at a flow rate of 15 mL / min. Baseline separation was obtained. Enantiomer 1 eluted at 29.7-30.1 min and Enantiomer 2 eluted at 30.2-30.9 min. Fractions for each enantiomer were combined and evaporated to give Enantiomer 1 (3.2 mg) and Enantiomer 2 (3.2 mg).
[0141] Example 2-Synthesis of (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid (SI2) Step 1: Synthesis of (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid (C) [ka] 4-(Trifluoroacetyl)benzoic acid (B) (82.41 mg, 0.38 mmol) was added to a stirred solution of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (70 mg, 0.38 mmol) in DMF (1.75 mL) at 25-30 °C, followed by DIPEA (0.263 mL, 1.52 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.72 mL, 1.14 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0142] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and then the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to obtain the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to obtain the pure product (C) as a light brown thick oil.
[0143] Yield: 68mg, (46.7%) 1 H-NMR-CD3OD(400MHz):δ:1.03(9H,s),1.27(3H,t,J=7.2Hz),4.21(2H,t,J=7.2Hz),4.85 -4.89(1H,m),5.57-5.59(1H,m),5.90-5.94(1H,m),7.71-7.80(2H,m),7.78-7.93(2H,m); LCMS: 404.3 [M+H+H2O] +
[0144] Step 2: Synthesis of (3E)-5,5-dimethyl-2-{[4-(2,2,2-trifluoroacetyl)phenyl(]formamido-hex-3-enoic acid (D) [ka] Lithium hydroxide monohydrate (35.38 mg, 0.85 mmol) was added to a stirred solution of compound C (65 mg, 0.17 mmol) in THF / methanol / water (1.95 mL, 1:1:1, 0.65 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0145] After 18 hours, the reaction mixture was concentrated, the residue was dissolved in water, washed with ethyl acetate (10 mL), the aqueous layer was acidified to pH 3.4 using 1.5N HCl, and the product was then extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The crude solid was washed with hexanes (5 mL) and DCM (5 mL) to give the final product D as an off-white solid.
[0146] Yield: 18mg, (29.9%) 1 H-NMR-DMSO-d6(400MHz):δ:1.0(9H,s),4.91(1H,d,J=9.6Hz),5.52-5.56(1H,m),5 .81-5.88(1H,m),7.68-7.81(1H,m),8.09-8.21(3H,m),9.13(1H,m),12.67(1H,bs); LCMS: 376.2 [M+H+H2O] + HPLC purity: 86.6%
[0147] Example 3-Synthesis of (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI3) Step 1: Synthesis of tert-butyl 2-methoxycarbonyl-4-(2-pyridyl)-1-piperazinecarboxylate (C) [ka] 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 0.084 g, 0.00013 mol), Pd(OAc)2 (0.03 g, 0.00013 mol) and potassium t-butoxide (0.30 g, 0.0027 mol) were added to a degassed solution of 2-bromopyridine (A) (0.21 g, 0.0013 mol) and N-Boc-piperazine-2-carboxylic acid methyl ester (B) (1.0 g, 0.0040 mol) in toluene (10 mL) at 25-30 °C. Degassing was continued for an additional 5 min. The resulting reaction mixture was heated at 85 °C for 18 h. The progress of the reaction was monitored by TLC.
[0148] After completion of the reaction, the reaction mixture was diluted with water (10 mL), ethyl acetate (10 mL) and the product was extracted into ethyl acetate (2×20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuum at 35° C. to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give product C as a pale yellow thick oil.
[0149] Yield: 0.18g, (impurities) LCMS: 322.2 [M+H] +
[0150] Step 2: Synthesis of 1-tert-butoxycarbonyl-4-(2-pyridyl)-2-piperazinecarboxylic acid (D) [ka] Lithium hydroxide monohydrate (0.11 g, 0.0028 mol) was added to a stirred solution of compound C (0.18 g, 0.00056 mol) in THF / methanol / water (5.4 mL, 1:1:1, 1.8 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0151] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with methyl tert-butyl ether (MTBE, 20 mL), and the aqueous layer was neutralized to pH 6-7 using 1.5 N HCl and concentrated to give the crude product, which was purified by reverse phase HPLC (RP-HPLC) to give pure D as a white solid.
[0152] Yield: 60mg, (35.3%) 1 H-NMR-DMSO-d6(400MHz):δ:1.39(9H,d,J=19.2Hz),2.78-2.80(1H,m),2.99-3.07(2H,m),3.77-3.79(1H,m),4.11-4.1 5(1H,m),4.59-4.69(2H,m),6.64-6.68(1H,m),6.78-6.81(1H,m),7.51-7.55(1H,m),8.08-8.10(1H,m),12.9(1H,bs); LCMS: 308.2 [M+H] + ;
[0153] Step 3: Synthesis of tert-butyl 2-{[(3E)-1-ethoxy-5,5-dimethyl-1-oxohex-3-en-2-yl]carbamoyl}-4-(pyridin-2-yl)piperazine-1-carboxylate (F) [ka] Ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (E) (39.18 mg, 0.22 mmol) was added to a stirred solution of compound D (65 mg, 0.2114 mmol) in DMF (1.62 mL) at 25-30 °C, followed by DIPEA (0.14 mL, 0.85 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.40 mL, 0.64 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0154] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give the product F as a pale yellow thick oil.
[0155] Yield: 50g, (impurities) 1 H-NMR-CD3OD(400MHz):δ:0.87-0.89(9H,m),1.24(3H,t,J=3.6Hz),1.46(9H,s),3.46-3.51(2H,m),3.93-4.2(5H,m),4.67-4 .79(2H,m),5.42-5.49(2H,m),5.69-5.82(1H,m),6.65-6.67(1H,m),6.80-6.86(1H,m),7.51-7.55(1H,m),8.08-8.10(1H,m); LCMS: 475.4 [M+H] +
[0156] Step 4: Synthesis of (E)-2-[1-tert-butoxycarbonyl-4-(2-pyridyl)-2-piperazinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (G) [ka] Lithium hydroxide monohydrate (22.1 mg, 0.53 mmol) was added to a stirred solution of compound F (50 mg, 0.11 mmol) in THF / methanol / water (1.5 mL, 1:1:1, 0.5 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0157] After 18 hours, the reaction mixture was concentrated, the residue was dissolved in water and washed with ethyl acetate (10 mL), the aqueous layer was acidified to pH 3.4 using 1.5N HCl, and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give the crude solid product. The crude solid product was washed with hexanes (5 mL) and DCM (5 mL) to give G as a light brown solid.
[0158] Yield: 35mg, (57.8%) 1 H-NMR-CD3OD(400MHz):δ:0.98(9H,s),1.46(9H,s),3.59-3.65(2H,m),3.91-3.99(1H,m),4.01-4.06(1H,m),4.69-4.72( 2H,m),5.44-5.51(1H,m),5.67-5.79(1H,m),6.66-6.69(1H,m),6.81-6.85(1H,m),7.55-7.59(1H,m),8.02-8.06(1H,m); LCMS: 447.4 [M+H] +
[0159] Step 5: Synthesis of (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (H) [ka] A 4M HCl in 1,4-dioxane solution was added to a stirred solution of compound G (35 mg, 0.0783 mmol) in 1,4-dioxane (0.2 mL) at 25-30° C. The resulting reaction mixture was stirred for 5 h at 25-30° C. The progress of the reaction was monitored by TLC.
[0160] After 5 h, the reaction mixture was concentrated. The resulting solid was washed with hexane (5 mL) and diethyl ether (5 mL) to give a crude mixture of two diastereomers of product H. The crude mixture was purified by RP-HPLC to give the two pure diastereomers of H as a white solid.
[0161] Yield: 4.2mg (diastereomer-1) and 5.3mg (diastereomer-2) LCMS: 347.3 [M+H] + ;
[0162] Example 4-Synthesis of (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (SI4) Step 1: Synthesis of tert-butyl 2-methoxycarbonyl-4-phenyl-1-piperazinecarboxylate (C) [ka] BINAP (0.015 g, 0.00002 mol), Pd2(dba)3 (0.011 g, 0.00001 mol) and cesium carbonate (0.32 g, 0.0010 mol) were added to a solution of 4-bromopyridine (A) (0.1 g, 0.0006 mol) and tert-butyl 2-methoxycarbonyl-1-piperazinecarboxylate (B) (0.15 g, 0.0006 mol) in toluene (4 mL) at 25-30 °C. The resulting reaction mixture was heated at 80 °C for 40 h. The progress of the reaction was monitored by TLC.
[0163] After completion of the reaction, the reaction mixture was diluted with ethyl acetate (10 mL) and filtered through a plug of Celite. The filtrate was concentrated under reduced pressure at 35° C. to give the crude product, which was purified by CombiFlash® using DCM / methanol as eluent to give compound C as a yellow thick oil.
[0164] Yield: 0.19g, (96.4%) 1 H-NMR-DMSO-d6(400MHz):δ:1.22-1.42(9H,m),2.87-3.08(1H,m),3.13-3.18(2H,m),3.55-3.59(3H,m) ,3.75-3.80(2H,m),4.23-4.33(1H,m),4.66-4.74(1H,m),6.81(2H,d,J=6.4Hz),8.17(2H,d,J=6.4Hz); LCMS: 322.2 [M+H] +
[0165] Step 2: Synthesis of 1-tert-butoxycarbonyl-4-(4-pyridyl)-2-piperazinecarboxylic acid (D) [ka] Lithium hydroxide monohydrate (0.12 g, 0.0029 mol) was added to a stirred solution of compound C (0.19 g, 0.0005 mol) in THF / methanol / water (5.7 mL, 1:1:1, 1.9 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0166] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with MTBE (20 mL). The aqueous layer was neutralized to pH 6-7 using 1.5 N HCl and concentrated to give the crude product, which was purified by RP-HPLC to give pure compound D as a white solid.
[0167] Yield: 0.15g, (87.0%) 1 H-NMR-DMSO-d6(400MHz):δ:1.37-1.42(9H,m),3.25-3.27(4H,m),3.13-3.18(11H,m),3 .55-3.61(2H,m),4.62-4.72(2H,m),7.16-7.32(2H,m),8.26-8.37(2H,m)13.45(2H,bs); LCMS: 308.0 [M+H] +
[0168] Step 3: Synthesis of tert-butyl 2-{[(3E)-1-ethoxy-5,5-dimethyl-1-oxohex-3-en-2-yl]carbamoyl}-4-(pyridin-4-yl)piperazine-1-carboxylate (F) [ka] Ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (E) (90.42 mg, 0.4880 mmol) was added to a stirred solution of compound D (150 mg, 0.4880 mmol) in DMF (3.75 mL) at 25-30 °C, followed by DIPEA (0.33 mL, 1.9521 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.93 mL, 1.4640 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0169] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted using ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure at 35°C to obtain the crude material, which was purified by CombiFlash® using DCM / methanol as eluent to give compound F as a pale yellow thick oil.
[0170] Yield: 105mg, (45.3%) 1 H-NMR-DMSO-d6(400MHz):δ:0.87-0.92(9H,m),1.18-1.21(m,3H),1.34-1.41 (9H,m),3.50-3.12(1H,m),3.47-3.52(2H,m),3.74-3.79(2H,m),4.04-4.23( 3H,m),4.19-4.23(0.5H,m),4.49-4.51(0.5H,m),4.68-4.70(1H,m),5.36-5. 41(1H,m),5.74-5.76(1H,m),6.76(2H,bs),8.13(2H,bs),8.67-8.68(1H,m); LCMS: 475.4 [M+H] +
[0171] Step 4: Synthesis of (E)-2-[1-tert-butoxycarbonyl-4-(4-pyridyl)-2-piperazinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (G) [ka] Lithium hydroxide monohydrate (44.20 mg, 1.05 mmol) was added to a stirred solution of compound F (100 mg, 0.21 mmol) in THF / methanol / water (3 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0172] After 18 hours, the reaction mixture was concentrated and the residue was dissolved in water and washed with ethyl acetate (10 mL). The aqueous layer was acidified to pH 3-4 using 1.5N HCl and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure at 40° C. to give a crude solid material, which was triturated with hexane (5 mL) and DCM (5 mL) respectively to give compound G as an off-white solid.
[0173] Yield: 27mg 1 H-NMR-DMSO-d6(400MHz):δ:0.88-0.98(9H,m),1.37-1.42(9H,m),3.59-3.65(2H,m),3.91-3.99(1H ,m),4.01-4.06(1H,m),4.63-4.71(1H,m),5.36-5.44(1H,m),6.88-6.91(2H,m),8.14-8.17(2H,m); LCMS: 447.4 [M+H] +
[0174] Step 5: Synthesis of (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid (H) [ka] A 4M HCl in 1,4-dioxane solution (0.5 mL) was added to a stirred solution of compound G (25 mg, 0.0559 mmol) in 1,4-dioxane (0.3 mL) at 25-30° C. The resulting reaction mixture was stirred for 5 h at 25-30° C. The progress of the reaction was monitored by TLC.
[0175] After 5 h, the reaction mixture was concentrated and the resulting solid material was triturated with hexane (5 mL) and diethyl ether (5 mL) to give a crude mixture which was purified by RP-HPLC to give the two diastereomers as white solids.
[0176] Yield: 2mg (isomer-1) and 1.9mg (isomer-2) LCMS: 347.3 [M+H] +
[0177] Example 5-Synthesis of (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexanoate (C) [ka] 6-Phenoxynicotinic acid (A) (100 mg, 0.23 mmol) was added to a stirred solution of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (86.08 mg, 0.23 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.32 mL, 0.92 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.88 mL, 0.69 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0178] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give compound C as a yellow thick oil.
[0179] Yield: 71.3 mg, (40.2%) 1 H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),1.16(3H,t,J=7.2Hz),4.10(2H,m),4.89-4.91(1H,m),5.52-5.54(1H,m),5.85(1H,d,J=14.4Hz),7 .08-7.10(1H,m),7.17-7.23(2H,m),7.24-7.27(1H,m),7.41-7.45(2H ,m),8.28(1H,d,J1=2.8Hz,J2=8.8Hz),8.62-8.63(1H,m),8.96(1H,s) LCMS: 383.3 [M+H] +
[0180] Step 2: Synthesis of (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (21.94 mg, 0.52 mmol) was added to a stirred solution of compound C (100 mg, 0.26 mmol) in THF / methanol / water (3 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 5 h. The progress of the reaction was monitored by TLC.
[0181] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with diethyl ether (10 mL), the aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl, and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give the crude solid material, which was washed with hexanes (5 mL) to give the crude product (mixture of two isomers) as an off-white solid. The crude material was purified by RP-HPLC to give compound D as a white solid.
[0182] Yield: 19mg 1H-NMR-DMSO-d6(400MHz):δ:0.96(9H,s),4.68(1H,t,J=6.0Hz),5.51-5.64(2H,m),7.06(1H,d,J=8.8Hz),7.15-7 .17(2H,m),7.22-7.25(1H,m),7.41-7.45(2H,m),8.26-8.28(2H,m),8.41(1H,d,J=6.4Hz),8.61(1H,d,J=2.4Hz); LCMS: 355.3 [M+H] + ;HPLC purity -99.5%.
[0183] Separation of the enantiomers of (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid (SI5) The separation was carried out in a similar manner as described above in Example 1, starting with 250 mg of crude racemic (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid. The preparative column was a CHIRALPAK-IG (250×30 mm) and elution was carried out with hexane / EtOAc / MeOH / TFA in the ratio 70 / 15 / 15 / 0.1. The flow rate was 40 mL / min and detection UV was at 245 mm. The feed concentration was 10 mg / mL and the injection volume was 5 mL (50 mg on column). The retention time of enantiomer 1 was 4.2 min and that of enantiomer 2 was 4.6 min. A CHIRALPAK-IG (250×4.6 mm) was used as the analytical column.
[0184] The separation gave 60 mg of enantiomer 1 with 99.9% HPLC purity and 58 mg of enantiomer 2 with 99.4% HPLC purity.
[0185] Example 6-Synthesis of (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI6) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexanoate (C) [ka] m-(4H-1,2,4-triazol-4-yl)benzoic acid (A) (120 mg, 0.64 mmol) was added to a stirred solution of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (122.5 mg, 0.64 mmol) in DMF (3 mL) at 25-30 °C, followed by DIPEA (0.45 mL, 2.59 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.23 mL, 1.94 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0186] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product, which was purified by RP-HPLC to give compound C as a clear thick oil.
[0187] Yield: 70mg, (31.0%) 1 H-NMR-DMSO-d6(400MHz):δ:1.06(9H,s),1.17(3H,t,J=7.2Hz),4.14(2H,t,J=7.2Hz),4.92-4.94(1H,m),5.54-5.57( 1H,m),5.90(1H,d,J=14.4Hz),7.66-7.70(1H,m),7.87-7.93(2H,m),8.17(1H,t,J=1.6Hz),9.02(1H,m),9.17(2H,s); LCMS: 357.3 [M+H] +
[0188] Step 2: Synthesis of (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (16.57 mg, 0.39 mmol) was added to a stirred solution of compound C (70 mg, 0.19 mmol) in THF / methanol / water (2.1 mL, 1:1:1, 0.7 mL each). The resulting reaction mixture was stirred at 25-30 °C for 5 h. The progress of the reaction was monitored by TLC.
[0189] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with diethyl ether (10 mL), and the aqueous layer was acidified using 1.5 N HCl to pH ∼5-6. The precipitate that formed was collected by vacuum filtration and washed with water (5 mL) and hexanes (5 mL) to give compound D as a white solid.
[0190] Yield: 28mg (43.2%) 1 H-NMR-DMSO-d6(400MHz):δ:1.00(9H,s),4.91-4.95(1H,m),5.52-5.58(1H,m),5.83-5.87(1H,m),7 .65-7.69(1H,m),7.87-7.96(2H,m),8.16(1H,t,J=1.6Hz),9.02(1H,m),9.17(2H,s);12.72(1H,bs); LCMS: 329.3 [M+H] + HPLC purity -90.7%
[0191] Example 7-Synthesis of (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (SI7) Step 1 Synthesis of methyl 2-azido-3-(2-chloro-6-methyl-3-pyridyl)acrylate (C) [ka] A solution of sodium methoxide (25 wt % in methanol) (62.49 mL, 0.2898 mol) was added dropwise over 20 min to a stirred solution of 2-chloro-6-methylnicotinaldehyde (A) (5.0 g, 0.032 mol) and ethyl azidoacetate (B) (9.26 mL, 0.080 mol) in methanol (50 mL) at -20°C to -30°C. The resulting reaction mixture was stirred at 0-5°C for 5 h. The progress of the reaction was monitored by TLC.
[0192] After completion of the reaction, the reaction mixture was quenched with ice-cold NH4Cl solution and stirred at 5-10 °C for 1 h to give a solid precipitate. The solid was collected by vacuum filtration, washed with water and dried to give compound C as a pale yellow solid.
[0193] Yield: 1.88g, (23.2%) 1 H-NMR-DMSO-d6(400MHz):δ:2.46(3H,s),3.87(3H,s),6.99(1H,s),7.36(1H,d,J=10.8Hz),8.46(1H,d,J=10.8Hz); LCMS: 352.8 [M+H] +
[0194] Step 2 Synthesis of methyl 4-chloro-6-methyl-1H-1,5-diazaindene-2-carboxylate (D) [ka] A solution of compound C (1.8 g, 0.0071 mol) in o-xylene (45 mL) was heated at 120° C. for 4 h. After 4 h, the heat was turned off and the reaction mixture was allowed to stand at 25-30° C. for 16 h (a solid precipitate formed).
[0195] The solid was collected by vacuum filtration, washed with hexanes (50 mL) and dried under reduced pressure to give compound D as a pale yellow solid.
[0196] Yield: 0.85g, (53.5%) 1H-NMR-DMSO-d6(400MHz):δ:3.88(3H,s),7.12(1H,s),7.22(1H,s),12.59(1H,s); LCMS: 224.6 [M+H] +
[0197] Step 3 Synthesis of methyl 6-methyl-1H-1,5-diazaindene-2-carboxylate (E) [ka] 10% Pd / C (0.17 g, 0.2% w / w) was added to a degassed solution of compound D (0.85 g, 0.0037 mol) in MeOH (30.6 mL) and THF (10.2 mL) at 25-30° C. The resulting reaction mixture was stirred under H2 atmosphere for 4 h. The progress of the reaction was monitored by TLC.
[0198] After completion of the reaction, the reaction mixture was filtered through a plug of Celite, and then the Celite plug was washed with MeOH (50 mL). The combined filtrate was evaporated to dryness to give the crude product (HCl salt) (0.8 g). The crude solid product was stirred with saturated NaHCO3 solution and DCM at 25-30 °C for 1 h. After 1 h, the layers were separated and the organic layer was dried over sodium sulfate and concentrated at 40 °C to give compound E as a pale yellow solid.
[0199] Yield: 0.69mg, (95.9%) 1 H-NMR-DMSO-d6(400MHz):δ:3.88(3H,s),7.12(1H,s),7.22(1H,s),12.59(1H,s); LCMS: 191.1 [M+H] +
[0200] Step 4: Synthesis of methyl 6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,5-diazaindene-2-carboxylate (F) [ka] Sodium hydride (60% dispersion in mineral oil) (0.16 g, 0.0039 mol) was added portionwise (in 4 portions) over 15 min to a stirred solution of compound E (0.69 g, 0.0036 mol) in THF (13.8 mL) and DMF (6.9 mL) at 0-5 °C. After stirring for 10 min, SEM-Cl (0.70 mL, 0.039 mol) was added dropwise at 0-5 °C. The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0201] After 18 h, the reaction mixture was quenched by addition of ice-cold water and the product was extracted into ethyl acetate (3×50 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The crude solid was purified by CombiFlash® using ethyl acetate / hexanes as eluent to give the pure product F as a brown thick oil.
[0202] Yield: 0.55g (47.4%) 1 H-NMR-DMSO-d6(300MHz):δ:-0.13(9H,s),0.75(2H,t,J=10.4Hz),2.55(3H,s),3.4 1(2H,t,J=2.0Hz),3.85(3H,s),5.90(2H,s),7.43(1H,s),7.54(1H,s),8.86(1H,s); LCMS: 321.3 [M+H] +
[0203] Step 5: Synthesis of 6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,5-diazaindene-2-carboxylic acid (G) [ka] Lithium hydroxide monohydrate (0.19 g, 0.0046 mol) was added to a stirred solution of compound F (0.3 g, 0.0009 mol) in THF / methanol / water (9 mL, 1:1:1, 3 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0204] After 18 h, the reaction mixture was concentrated, the remaining residue was dissolved in water and washed with MTBE (20 mL), and the aqueous layer was neutralized to pH ∼5-6 using 1.5 N HCl to give a solid precipitate. The solid was collected by vacuum filtration, washed with water, and dried at 40 °C to give compound G as a light brown solid.
[0205] Yield: 0.24g (83.9%) 1 H-NMR-DMSO-d6(400MHz):δ:-0.13(9H,s),0.80(2H,t,J=8.0Hz),2.70(3H,s),3.47 (2H,t,J=7.6Hz),6.01(2H,s),7.59(1H,s),8.02(1H,s),9.20(1H,s),14.56(1H,bs) LCMS: 307.2 [M+H] +
[0206] Step 6 Synthesis of ethyl (E)-5,5-dimethyl-2-(6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexanoate (I) [ka] Ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (H) (96.73 mg, 0.5221 mmol) was added followed by HATU (297.8 mg, 0.7832 mmol), HOBt (105.8 mg, 0.7832 mmol) and DIPEA (0.18 mL, 1.0442 mmol) to a stirred solution of compound G (160 mg, 0.5221 mmol) in DMF (3.2 mL) at 25-30 °C. The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0207] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and then the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to obtain the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to obtain compound I as a yellow thick oil.
[0208] Yield: 83mg (29.4%) 1 H-NMR-DMSO-d6(400MHz):δ:-0.14(9H,S),0.73(2H,t,J=10.4Hz),0.99(9H,S),1.18(3H,t,J=7.22Hz),2.54(3H,s),3.37(2H,m),4.04- 4.14(2H,m),4.87(1H,t,J=7.2Hz),5.55-5.72(1H,m),5.87-5.90(3H,m),7.33(1H,s),7.45(1H,s),8.83(1H,s),9.10(1H,d,J=7.2Hz); LCMS: 474.4 [M+H] +
[0209] Step 7: Synthesis of (E)-5,5-dimethyl-2-(6-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (J) [ka] Lithium hydroxide monohydrate (35.4 mg, 0.8444 mmol) was added to a stirred solution of compound I (80 mg, 0.1688 mmol) in THF / methanol / water (2.4 mL, 1:1:1, 0.8 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0210] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with ethyl acetate (10 mL), and the aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl at 0-5° C. (a solid precipitated). The solid was collected by vacuum filtration, washed with water, and dried at 40° C. to give pure compound J as an off-white solid.
[0211] Yield: 44mg (58.5%) 1 H-NMR-DMSO-d6(400MHz):δ:-0.13(9H,S),0.75(2H,t,J=1.6Hz),1.0(9H,S),2.69(3H,s),3.44(2H,t,J=6.8Hz),4.91(1H,t,J=6.4Hz ),5.51-5.55(1H,m),5.82-5.85(1H,m),6.0-6.02(2H,m),7.58(1H,s),7.97(1H,s),9.24-9.32(1H,m),12.87(1H,bs),15.34(1H,bs); LCMS: 446.2 [M+H] +
[0212] Step 8: Synthesis of (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid (K) [ka] A 4M HCl in 1,4-dioxane solution (0.8 mL) was added to a stirred solution of compound J (40 mg, 0.0897 mmol) in 1,4-dioxane (0.4 mL) at 25-30° C. The resulting reaction mixture was stirred for 18 h at 25-30° C. The progress of the reaction was monitored by TLC.
[0213] After 18 h, the reaction mixture was concentrated. The resulting solid was washed with hexane (5 mL) and diethyl ether (5 mL) to give the crude product, which was purified by RP-HPLC to give pure compound K as a white solid.
[0214] Yield: 8mg (28.3%) 1H-NMR-DMSO-d6(400MHz):δ:1.0(9H,S),2.49(3H,s),4.90(1H,t,J=6.0Hz),5.53-5.55(1 H,m),5.79(1H,t,J=15.6Hz),7.17(1H,s),7.35(1H,s),8.79-8.84(3H,m),11.83(1H,bs); LCMS: 316.3 [M+H] + ;HPLC purity 93.5%.
[0215] Example 8 - Synthesis of (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI8) Step 1: Synthesis of 4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrolecarboxylic acid (B) [ka] K2CO3 (0.99 g, 0.0072 mol) and 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) (0.43 mL, 0.0024 mol) were added to a stirred solution of 4-chloro-1H-pyrrole-2-carboxylic acid (A) (0.3 g, 0.0020 mol) in DMF (3 mL) at 25-30 °C. The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0216] After completion of the reaction, the reaction mixture was filtered through a plug of Celite. The filtrate was concentrated under reduced pressure at 40° C. Upon concentration, a thick oily mass was obtained, which was dissolved in water and the pH of the solution was adjusted to 3-4 using 1.5N HCl solution. The product was extracted using ethyl acetate (3×10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure at 40° C. to obtain the crude product. This was further purified by using CombiFlash® using ethyl acetate / hexane as eluent to obtain product B as a clear thick oil.
[0217] Yield: 0.22g (38.7%) 1H-NMR-DMSO-d6(400MHz):δ:0.11(9H,s),0.89(2H,t,J=9.4Hz),3.72(2H,t, J=8.8Hz),5.38(2H,s),6.79-6.80(1H,m),7.17-7.18(1H,m),12.3(1H,bs); LCMS: No ionization observed
[0218] Step 2: Synthesis of ethyl (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexanoate (D) [ka] Oxalyl chloride (0.1 mL, 0.0011 mol) was added dropwise to a stirred solution of compound B (0.3 g, 0.0009 mol) in DCM (6 mL) along with a catalytic amount of DMF (0.12 mL) at 0-5° C. The resulting reaction mixture was stirred at 25-30° C. for 2 h. The progress of the reaction was monitored by TLC.
[0219] After 2 h, the reaction mixture was concentrated to dryness at 35° C. and the remaining water was removed with toluene (3×5 mL). This gave a thick yellow oil, which was further dissolved in DCM (3 mL) and added to a stirred solution of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (C) (0.16 g, 0.0009 mol) and DIPEA (0.62 mL, 0.0036 mol) in DCM (3 mL) at 25-30° C. The resulting reaction mixture was stirred at 25-30° C. for 18 h. The progress of the reaction was monitored by TLC.
[0220] After 18 hours, the reaction mixture was quenched by the addition of saturated NaHCO3 solution (15 mL) and the product was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure at 35°C to give the crude product as a light brown thick oil. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give the pure product D as a yellow thick oil.
[0221] Yield: 40 mg (14.3% for 2 steps) 1 H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),1.15(3H,t,J=7.2Hz),4.05-4.14(2H,m),4.84-4.88(1H, m),5.45-5.50(1H,m),5.74-5.83(1H,m),6.94-6.98(2H,m),8.47(1H,t,J=6.8Hz);11.89(1H,bs).
[0222] Step 3: Synthesis of (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (E) [ka] Lithium hydroxide monohydrate (10.73 mg, 0.255 mmol) was added to a stirred solution of compound D (40 mg, 0.1278 mmol) in THF / methanol / water (1.2 mL, 1:1:1, 0.4 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0223] After 18 h, the reaction mixture was concentrated, the remaining residue was dissolved in water, washed with ethyl acetate (10 mL), and the aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl at 0-5°C. The product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40°C to give a crude solid. The crude mixture was purified by RP-HPLC to give product E as a white solid.
[0224] Yield: 3.8mg LCMS: 285.2 [M+H] +
[0225] Example 9 - Synthesis of (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI9) Step 1: Synthesis of ethyl (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 3-Isobutyl-1-methyl-5-pyrazole carboxylic acid (A) (100 mg, 0.27 mmol) was added to a stirred solution of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (101.6 mg, 0.27 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.38 mL, 1.09 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.04 mL, 0.82 mmol). The reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0226] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure at 35 °C to give the crude product, which was purified by CombiFlash using ethyl acetate / hexane as eluent to give compound C and a mixture of isomers as a yellow thick oil.
[0227] Yield: 66.6mg (34.8%) 1 H-NMR-DMSO-d6(400MHz):δ:(mixture of isomers)0.88-0.90(9H,s),0.97(9H,s),1.20-1.23(6H,m),1.82-1.86(1H,m),2.37-2.40(3H,m),3.93(3H,s) ,4.07-4.14(2H,m),4.81-4.83(1H,m),5.49-5.51(1H,m),5.81-5.86( 1H,m),6.58(0.29H,m),6.77(1.31H,m),8.79(1H,m),9.59(0.29H,m); LCMS: 350.3 [M+H] +
[0228] Step 2: Synthesis of (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (24.01 mg, 0.57 mmol) was added to a stirred solution of compound C (100 mg, 0.28 mmol) in THF / methanol / water (3 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 5 h. The progress of the reaction was monitored by TLC.
[0229] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid, which was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The mixture was purified by RP-HPLC to give pure compound D as a white solid.
[0230] Yield: 23.4mg 1 H-NMR-DMSO-d6(400MHz):δ:0.83(6H,d,J=6.4Hz),0.91(9H,s),1.78-1.82(1H,m),2.34(2H,d,J =7.2Hz),3.93(3H,s),4.50-4.53(1H,m),5.46-5.58(2H,m),6.64(1H,s),8.04(1H,d,J=5.2Hz); LCMS: 322.3 [M+H] + HPLC purity -99.76%
[0231] Example 10 Synthesis of 10-(E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid (SI13) Step 1: Synthesis of 1-(2-pyridyl)-2-propyn-1-ol (B) [ka] A solution of 2-pyridinecarboxaldehyde (A) (2.0 g, 0.018 mol) predissolved in THF (6.0 mL) was added dropwise to a stirred solution of ethynylmagnesium bromide solution (0.5 M in THF) (44.7 mL, 0.0224 mol) over 15-20 min at -10 °C to -15 °C. The resulting reaction mixture was stirred at -5 °C to -10 °C for 1 h and at 25-30 °C for 1 h. The progress of the reaction was monitored by TLC.
[0232] After completion of the reaction, the reaction mixture was quenched with saturated NH4Cl solution (100 mL) and the product was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuum at 40°C to give the crude product. The crude solid was purified by CombiFlash® using ethyl acetate / hexane as eluent to give product B as a brown oil.
[0233] Yield: 1.56g (63.2%) 1 H-NMR-CDCl3(300MHz):δ:2.59(1H,d,J=2.8Hz),5.53(1H,d,J=2.8Hz),7.31- 7.37(1H,m),7.56(1H,d,J=10.4Hz),7.77-7.82(1H,m),8.58(1H,t,J=5.2Hz); LCMS: 134.23 [M+H] +
[0234] Step 2: Synthesis of ethyl 4-[(2-pyridyl)carbonyl]-2-pyrrolecarboxylate (C) [ka] Silver carbonate (0.414 g, 0.0015 mol) was added to a stirred solution of compound B (1.5 g, 0.011 mol) and ethyl isocyanoacetate (0.849 ml, 0.011 mol) in 1,4-dioxane at 80° C. The resulting reaction mixture was stirred at 80° C. for 16 hours. The progress of the reaction was monitored by TLC.
[0235] After completion, the reaction mixture was evaporated to dryness at 40° C. The resulting residue was dissolved in DCM (50 mL) and the solution was filtered through a Celite plug. The DCM layer was washed with saturated sodium chloride solution (2×50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo at 40° C. to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexanes as eluent to give the product (C) as a brown thick oil.
[0236] Yield: 0.16g (6%) 1 H-NMR-CDCl3(400MHz):δ:1.33(3H,t,J=6.8Hz),4.35(2H,q,J=5.6Hz),7.27-7.49(1H,m),7.71(1H,d,J =1.2Hz),7.86-7.90(1H,m),8.13-8.15(1H,m),8.32(1H,d,J=3.2Hz),8.71-8.74(1H,m),9.55(1H,bs); LCMS: 245.28 [M+H] +
[0237] Step 3: Synthesis of ethyl 4-[(2-pyridyl)carbonyl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrole-carboxylate [ka] K2CO3 (226.3 mg, 1.6377 mmol) followed by 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) (0.13 ml, 0.786 mmol) were added to a stirred solution of compound C (160 mg, 0.655 mmol) in DMF (3.2 mL) at 25-30 °C. The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0238] After completion of the reaction, the mixture was diluted with water (10 mL) and the product was extracted with ethyl acetate (3×10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuum at 40° C. to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to give the product (D) as a clear thick oil.
[0239] Yield: 50mg, (20.4%) 1 H-NMR-CDCl3(400MHz):δ:-0.08(9H,s),0.94(2H,t,J=8.4Hz),1.38(3H,t,J=6.8Hz),3.60(2H,t,J=8.0Hz),4.34(2H,q,J=7.2Hz),5.7 7(2H,s),7.46-7.49(1H,m),7.86(1H,d,J=1.6Hz),7.88-7.90(1H,m),8.13-8.15(1H,m),8.72(1H,d,J=1.6Hz),8.73(1H,d,J=2.0Hz); LCMS: 375.3 [M+H] +
[0240] Step 4: Synthesis of ethyl 4-[(tert-butylsulfinylimino)(2-pyridyl)methyl]-1-{[2-(trimethylsilyl)-ethoxy]methyl}-2-pyrrolecarboxylate (E) [ka] tert-Butanesulfinamide (126.2 mg, 1.041 mmol) and Ti(OEt)4 (0.36 mL, 1.735 mmol) were added to a stirred solution of compound D (130 mg, 0.347 mmol) in dry THF (1.95 mL) at 25-30 °C. The resulting reaction mixture was heated at 80 °C for 18 h. The progress of the reaction was monitored by TLC.
[0241] After completion of the reaction, the reaction mixture was quenched with ice-cold water (5 mL) and the product was extracted into ethyl acetate (3×5 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuum at 40° C. to obtain the crude product. The crude product was purified by CombiFlash® using ethyl acetate / hexane as eluent to obtain compound E as a yellow oil.
[0242] Yield: 110mg, (66.3%) 1 H-NMR-DMSO-d6(400MHz):δ:-0.09(9H,s),0.92(2H,t,J=8.2Hz),1.15(9H,s),1.25(3H,t,J=6.8Hz),3.44(2H,t,J=7.6 Hz),4.23(2H,q,J=7.2Hz),5.62(2H,s),7.06(1H,bs),7.51-7.56(3H,m),7.93(1H,t,J=7.6Hz),8.66(1H,d,J=4.4Hz); LCMS: 478.2 [M+H] +
[0243] Step 5: Synthesis of ethyl 4-[(tert-butylsulfinylamino)(2-pyridyl)methyl]-1-{[2-(trimethylsilyl)-ethoxy]methyl}-2-pyrrolecarboxylate [ka] NaBH4 (435 mg, 1.151 mmol) was added to a stirred solution of compound E (110 mg, 0.230 mmol) in dry THF (2.2 mL) at -78 °C. The resulting reaction mixture was stirred at -40 °C to -60 °C for 5 h and at 25-30 °C for 6 h. The progress of the reaction was monitored by TLC.
[0244] After completion of the reaction, the reaction mixture was quenched with ice-cold water (5 mL) and the product was extracted into ethyl acetate (3×5 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuum at 40° C. to give crude compound F as a pale yellow oil. The crude material was used as is in the next reaction.
[0245] Yield: 100 mg (crude) 1 H-NMR-DMSO-d6(300MHz):δ:-0.10(9H,s),0.75(2H,t,J=10.4Hz),1.06-1. 26(12H,m),3.37(2H,t,J=2.8Hz),4.16(2H,q,J=3.6Hz),5.38-5.42(1H,s) ,5.54(2H,s),5.89-5.92(1H,s),6.76-6.78(1H,m),7.15(1H,d,J=2.8Hz), 7.26-7.31(1H,m),7.49-7.55(1H,m),7.77-7.71(1H,m),8.48-8.51(1H,m); LCMS: 480.3 [M+H] +
[0246] Step 6: Synthesis of 4-[(tert-butylsulfinylamino)(2-pyridyl)methyl]-1-{[2-(trimethylsilyl)-ethoxy]methyl}-2-pyrrolecarboxylic acid [ka] Lithium hydroxide monohydrate (41.54 mg, 0.990 mmol) was added to a stirred solution of compound F (95 mg, 0.198 mmol) in a mixture of THF / methanol / water (2.85 mL each, 0.95 mL each) at room temperature (20-25 °C). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0247] After completion of the reaction, the reaction mixture was evaporated to dryness. The resulting residue was dissolved in purified water (5 mL) and washed with MTBE (2×10 mL). The aqueous layer was acidified to pH about 5-6 using 0.5 N HCl solution and the product was extracted with ethyl acetate (3×15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated at 40° C. to obtain a crude solid. The crude solid was washed with hexane (5 mL) and diethyl ether (10 mL) to obtain crude compound G as an off-white solid. The crude compound was used as such in the next reaction.
[0248] Yield: 54 mg, (crude) 1 H-NMR-DMSO-d6(400MHz):δ:-0.10(9H,s),0.75(2H,t,J=7.6Hz),1.06-1.13(9H,m),3.39(2H,t,J=5.6Hz),5.42-5.44(1H,s),5.54(2H,s),5.89- 5.91(1H,s),6.72-6.79(1H,m),7.04-7.08(1H,m),7.25-7.28(1H,m),7. 45-7.49(1H,m),7.52-7.61(1H,m),7.76-7.79(1H,m),8.46-8.49(1H,m); LCMS: 452.3 [M+H] +
[0249] Step 7: Synthesis of (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid (I) (SI13) [ka] The final step of the synthesis of compound I started with the coupling of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (H) with the prepared compound G, followed by hydrolysis of the resulting ethyl ester and removal of the two remaining protecting groups, in the same manner as described above for steps 7 and 8 of example 7. The final product was isolated as a mixture of diastereomers.
[0250] Example 11 Synthesis of 1-(E)-5,5-dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid (SI16) Step 1: Synthesis of 1-(2-oxo-4-pyridyl)-4-pyrazole carboxylic acid (C) [ka] 4-Chloro-1H-pyridin-2-one (A) (200 mg, 1.54 mmol), ethyl 1H-pyrazole-4-carboxylate (B) (325 mg, 2.32 mmol) and cesium carbonate (760 mg, 2.33 mmol) were mixed in dry N-methyl-2-pyrrolidone (0.5 ml). The mixture was heated at 120° C. for 16 hours.
[0251] After the reaction was complete, ethyl acetate (3 mL) was added. The mixture was shaken and then centrifuged. The supernatant was removed, and more ethyl acetate (3 mL) was added, the mixture was shaken again, centrifuged, and the supernatant was removed. Water and NaOH (0.5 mL) were added, and the mixture was heated at 50° C. overnight. The mixture was then centrifuged and the supernatant was removed. Water was added, the mixture was shaken again, and centrifuged. The supernatant was removed. The resulting solid material was dried under vacuum at 45° C. to give 439 mg of a beige solid. By LC-MS and NMR, two compounds were detected in a 1:1 ratio, assigned to a mixture of compound C and its corresponding ethyl ester.
[0252] The crude mixture (50 mg) was dissolved in methanol (0.5 mL), aqueous NaOH (5 M, 0.5 mL) was added, and the mixture was heated at 60° C. for 2 h. The resulting mixture was acidified to pH 4-5 by adding aqueous HCl (5 M). The mixture was centrifuged and the supernatant was removed. Water and acetonitrile were added, and the solvent was evaporated. The crude solid compound C formed was used directly in the next step.
[0253] Step 2: Synthesis of (E)-5,5-dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid (E) (SI16) [ka] The final step in the synthesis of compound E was carried out in the same manner as described above for example 5, starting from the coupling of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate (D) with the prepared compound C, followed by hydrolysis of the resulting ethyl ester to give the expected product.
[0254] Example 1 Synthesis of 2-(E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI17) Step 1: Synthesis of ethyl (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexanoate (C) [ka] 2-(Dimethylamino)-5-pyrimidine carboxylic acid (B) (90.10 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.376 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.028 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0255] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude material was purified by RP-HPLC to give the pure product C as an off-white solid.
[0256] Yield: 25mg, 13.8% LCMS: 335.26 [M+H] +
[0257] Step 2: Synthesis of (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (15.69 mg, 0.37 mmol) was added to a stirred solution of compound C (25 mg, 0.07 mmol) in THF / methanol / water (0.75 mL, 1:1:1, 0.25 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0258] After 18 hours, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH approx. 5-6 using 1.5N HCl and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The crude material was washed with hexane (5 mL) to give pure compound D as a white solid.
[0259] Yield: 16.4mg 1 H-NMR-DMSO-d6(400MHz):δ:0.98(9H,s),3.17(6H,s),4.78-4.81(1H,m),5.49-5.54(1H,m),5.76(1H,d,J=16.4Hz),8.50(1H,bs)8.78(2H,s); LCMS: 307.3 [M+H] + ;HPLC purity -94.39%
[0260] Example 13 Synthesis of (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI49) Step 1: Synthesis of ethyl (E)-2-(2-isopropyl-4-methyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 2-Isopropyl-4-methyl-5-pyrimidine carboxylic acid (B) (144.16 mg, 0.80 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (150 mg, 0.80 mmol) in DMF (3.75 mL) at 25-30 °C, followed by DIPEA (0.55 mL, 3.2 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.52 mL, 2.4 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0261] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give the pure product C as a yellow thick oil.
[0262] Yield: 66mg (35.9%) 1 H-NMR-CD3OD(400MHz):δ:1.12(9H,s),1.39-1.46(9H,m),2.73(3H,s),3.28-3.32(1H,m),4.35-4.38(2 H,m),5.14(1H,d,J=7.5Hz),5.62-5.70(1H,m),6.07(1H,d,J=15.3Hz),6.94-7.26(1H,m),8.76(1H,s); LCMS: 348.3 [M+H] +
[0263] Step 2: Synthesis of (E)-2-(2-isopropyl-4-methyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (39.9 mg, 1.04 mmol) was added to a stirred solution of compound C (66 mg, 0.19 mmol) in THF / methanol / water (2.4 mL, 1:1:1, 0.8 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0264] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with diethyl ether (10 mL), the aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl, and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude material was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0265] Yield: 12mg 1 H-NMR-DMSO-d6(400MHz):δ:0.98(9H,s),1.24(6H,d),2.48(3H,s),3.05-3.12(1H,m),4.81-4.84(1H,m), 5.42-5.48(1H,m),5.81-5.85(1H,m),8.59(1H,s),8.94(1H,d,J=7.2Hz),12.74(1H,bs);LCMS:320.3[M+H] + ;HPLC purity: 94.9%.
[0266] Example 1 Synthesis of 4-(E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (SI23) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexanoate (C) [ka] p-(4H-1,2,4-triazol-4-yl)benzoic acid (B) (50.88 mg, 0.26 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (50 mg, 0.26 mmol) in DMF (1.25 mL) at 25-30 °C, followed by DIPEA (0.18 mL, 1.07 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.51 mL, 0.807 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0267] After the reaction was completed, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35 °C to give the crude product. The crude was purified by CombiFlash® using ethyl acetate:hexane as eluent to give pure compound C as a thick yellow liquid.
[0268] Yield: 50mg (52.0%) 1 H-NMR-CD3OD(300MHz):δ:0.98(9H,s),1.30-1.34(3H,m),4.19-4.25(2H,m),5.07-4.89(1H,m) ,5.58-5.65(1H,m),5.92-5.97(1H,m),7.80(2H,d,J=8.7Hz),8.09(2H,d,J=9Hz),9.13(2H,s); LCMS: 357.4 [M+H] +
[0269] Step 2: Synthesis of (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (29.46 mg, 0.70 mmol) was added to a stirred solution of compound C (50 mg, 0.14 mmol) in THF / methanol / water (1.5 mL, 1:1:1, 0.5 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0270] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude material was washed with hexanes (5 mL) to give a mixture of two isomers as an off-white solid. The crude material was purified by RP-HPLC to give pure compound D as a white solid.
[0271] Yield: 4.4 mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.9(9H,s),4.89-4.90(1H,t,J=6.4Hz),5.57-5.59(1H,m),5.80-5.84(1H,m),7.85-7.86 (2H,dd,J1=2Hz,J2=7.2Hz),8.07-8.08(1H,dd,J1=1.6Hz,J2=6.8Hz),8.89-8.91(1H,d),9.23(2H,s),12.63(1H,bs), LCMS: 329.4 [M+H] + ;HPLC purity 99.4%
[0272] Example 1 Synthesis of 5-(E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (SI24) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexanoate (C) [ka] m-(1H-1,2,4-triazol-1-yl)benzoic acid (B) (101.96 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.02 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0273] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a thick yellow liquid.
[0274] Yield: 64mg, (33.3%) 1 H-NMR-CD3OD(400MHz):δ:1.07(9H,s),1.24-1.30(3H,m),4.21-4.24(2H,m),5.05-5.07(1H,d,J=7.6Hz),5.60-5.64(1H, m),5.93-5.97(1H,m),7.66-7.70(1H,m),7.94(1H,d,J=7.6Hz),8.03-8.05(1H,m),8.21(1H,s),8.34(1H,s),9.17(1H,s); LCMS: 357.6 [M+H] +
[0275] Step 2: Synthesis of (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (37.69 mg, 0.8975 mmol) was added to a stirred solution of compound C (64 mg, 0.1795 mmol) in THF / methanol / water (1.92 mL, 1:1:1, 0.64 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0276] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude material was washed with hexanes (5 mL) to give a mixture of two isomers as an off-white solid. The mixture was purified by RP-HPLC to give compound D as a white solid.
[0277] Yield: 29mg 1 H-NMR-DMSO-d6(400MHz):δ:1.0(9H,s),4.90-4.94(1H,m),5.54-5.60(1H,m),5.83-5.87(1H,m),7.67(1H,t,J=8Hz),7.9 4(1H,d,J=8Hz),8.02-8.05(1H,m),8.28(1H,s),8.34(1H,t,J=1.6Hz),9.00(1H,d,J=7.2Hz),9.36(1H,s),12.60(1H,bs); LCMS: 329.3 [M+H] + ;HPLC purity -99.6%
[0278] Example 16 Synthesis of (E)-2-[m-(1-imidazolyl)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI25) Step 1: Synthesis of ethyl (E)-2-[m-(1-imidazolyl)benzoylamino]-5,5-dimethyl-3-hexanoate (C) [ka] m-(1-Imidazolyl)benzoic acid (B) (101.5 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0279] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give pure compound C as a brown thick oil.
[0280] Yield: 65mg, (33.9%) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),1.24(3H,t,J=7.2Hz),4.18-4.21(2H,m),5.02-5.04(1H,m),5.69-5.61(1H,m ),5.90-5.94(1H,m),7.16(1H,s),7.62-7.64(2H,m),7.77-7.79(1H,m),7.87-7.89(1H,m),8.05(1H,s),8.21(1H,s); LCMS: 356.3 [M+H] +
[0281] Step 2: Synthesis of (E)-2-[m-(1-imidazolyl)benzoylamino]-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (32.5 mg, 0.77 mmol) was added to a stirred solution of compound C (61 mg, 0.17 mmol) in THF / methanol / water (1.83 mL, 1:1:1, 0.61 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0282] After 18 h, the reaction mixture was concentrated, the residue was dissolved in water, washed with diethyl ether (10 mL), the aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl, and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting crude solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as a white solid. The crude mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0283] Yield: 20mg 1 H-NMR-DMSO-d6(400MHz):δ:1.22(9H,s),4.93-4.97(1H,m),5.52-5.60(1H,m),5.82-5.89(1H,m),7.23(1H ,s),7.61-7.67(1H,m),7.83-7.91(3H,m),8.13(1H,s),8.47(1H,s),8.94(1H,d,J=9.2Hz),12.63(1H,bs); LCMS: 328.3 [M+H] + ;HPLC purity -99.6%
[0284] Example 1 Synthesis of 7-(E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (SI51) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexanoate (C) [ka] p-(2-Thienyl)benzoic acid (B) (108.1 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0285] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a pale yellow thick oil.
[0286] Yield: 117mg (59.4%) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),1.24(3H,t,J=7.2Hz),4.19(2H,d,J=5.6Hz),5.01-5.03(1H,m),5.48 -5.53(1H,m),5.88-5.92(1H,m),7.10-7.14(1H,m),7.42-7.50(2H,m),7.71-7.73(2H,m),7.85-7.88(2H,m); LCMS: 372.10 [M+H] +
[0287] Step 2: Synthesis of (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (31.6 mg, 0.75 mmol) was added to a stirred solution of compound C (112 mg, 0.30 mmol) in MeOH:THF:water (3.3 mL, 1:1:1, 1.1 mL each). The resulting reaction mixture was stirred at 25-30 °C for 7 h. The progress of the reaction was monitored by TLC.
[0288] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexane (5 mL) to give a mixture of two isomers as a white solid. The crude product was purified by RP-HPLC to give pure compound D as a white solid.
[0289] Yield: 48mg; 1 H-NMR-DMSO-d6(400MHz):δ:1.00(9H,s),4.87-4.91(1H,m),5.53-5.61(1H,m),5.84(1H,d,J=20.8Hz),7.16 -7.19(1H,m),7.62-7.65(2H,m),7.74-7.77(2H,m),7.93-7.96(2H,m),8.81(1H,d,J=9.6Hz),12.62(1H,bs); LCMS: 344.4 [M+H] + ;HPLC purity -99.1%.
[0290] Example 18 Synthesis of (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (SI52) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexanoate (C) [ka] m-(2-Thienyl)benzoic acid (B) (109.96 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.02 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0291] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a thick yellow liquid.
[0292] Yield: 100mg, (49.8%) 1 H-NMR-CD3OD(400MHz):δ:1.04(9H,s),1.25(3H,t,J=6.8Hz),4.18-4.21(2H,m),5.03(1H,m),5.57-5.62(1H,m), 5.89-5.94(1H,m),7.09-7.11(1H,m),7.39-7.41(1H,m),7.45-7.49(2H,m),7.73-7.79(2H,m),8.11-8.12(1H,m); LCMS: 372.08 [M+H] +
[0293] Step 2: Synthesis of (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (56.51 mg, 1.34 mmol) was added to a stirred solution of compound C (100 mg, 0.26 mmol) in THF / methanol / water (3.0 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0294] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude mixture was purified by RP-HPLC to give pure compound D.
[0295] Yield: 52.8 mg; 1 H-NMR-DMSO-d6(400MHz):δ:1.01(9H,s),4.89-4.94(1H,m),5.54-5.62(1H,m),5.81-5.87(1H,d,J=15.6Hz),7.16-7.19( 1H,m),7.49-7.54(1H,m),7.60(2H,d,J=5.7Hz),7.83(2H,d,J=7.5Hz),8.14(1H,s),8.93(1H,d,J=6.9Hz),12.72(1H,bs); LCMS: 344.2 [M+H] + ;HPLC purity -99.8%.
[0296] Example 19 Synthesis of (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI28) Step 1: Synthesis of 4-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrole carboxylic acid (B) [ka] SEM-Cl (0.279 mL, 1.57 mmol) was added to a stirred solution of 4-bromo-2-pyrrole carboxylic acid (A) (250 mg, 1.31 mmol) in DMF (2.5 mL), followed by K2CO3 (653.6 mg, 4.71 mmol). The resulting reaction mixture was stirred at 25-30 °C for 2 h. The progress of the reaction was monitored by TLC.
[0297] After completion of the reaction, the reaction mixture was quenched by adding water, adjusted to pH about 5-6 with 1.5N HCl, and the product was extracted with ethyl acetate (2×40 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35° C. to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound B as a thick colorless liquid.
[0298] Yield: 239mg (56.7%) 1 H-NMR-DMSO-d6(300MHz):δ:-0.01(9H,s),0.89(2H,t,J=7.8Hz),3.73(2H,t,J=7.8Hz),5.37(2H,s),6.86(1H,s),7.21(1H,s),12.37(1H,bs)
[0299] Step 2: Synthesis of ethyl (E)-2-(4-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexanoate (D) [ka] Oxalyl chloride (0.092 mL, 1.12 mmol) was added dropwise to a stirred solution of compound B (300 mg, 0.94 mmol) in DCM (6.0 mL) along with a catalytic amount of DMF (0.12 mL) at 0-5 °C. The resulting reaction mixture was stirred at 25-30 °C for 2 h. The progress of the reaction was monitored by TLC (an aliquot was diluted with MeOH to confirm the formation of the methyl ester).
[0300] After 2 h, the reaction mixture was concentrated to dryness at 35° C. and stripped with toluene (5 mL×3). After complete concentration, a yellow thick oil was obtained. This was further dissolved in DCM (3 mL) and added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (C) (0.16 g, 0.0009 mol) and DIPEA (0.62 mL, 0.0036 mol) in DCM (3 mL) at 25-30° C. The resulting reaction mixture was stirred at 25-30° C. for 18 h. The progress of the reaction was monitored by TLC.
[0301] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound D as a thick yellow liquid.
[0302] Yield: 109 mg (21.9%); 1 H-NMR-DMSO-d6(400MHz):δ:1.02(9H,s),1.14-1.18(3H,m),4.10-4.13(2H,m),4.83-4.88(1H,m),5.44 -5.52(1H,m),5.75-5.85(1H,m),7.02(2H,s),8.49(1H,d,J=6.9Hz),11.88(1H,bs);LCMS:381.1[M+Na] + ;
[0303] Step 3: Synthesis of (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (E) [ka] Lithium hydroxide monohydrate (58.8 mg, 1.39 mmol) was added to a stirred solution of compound D (100 mg, 0.27 mmol) in THF / methanol / water (3.0 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0304] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude material was purified by RP-HPLC to give pure compound E as a pale yellow solid.
[0305] Yield: 5.2 mg; 1 H-NMR-DMSO-d6(300MHz):δ:0.99(9H,s),4.79(1H,m),5.48-5.55(1H,m),5.71-5.76(1H,m),6.99(2H,s),8.26(1H,bs),11.87(1H,bs); LCMS: 353.20 [M+Na] + ;HPLC purity -98.5%
[0306] Example 20 - Synthesis of (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI29) Step 1: Synthesis of methyl 5-chloro-2-pyrrolecarboxylate (B) [ka] A solution of t-butyl hypochlorite predissolved in CCl4 (40.1 mL) was added dropwise to a stirred solution of methyl 2-pyrrolecarboxylate (A) (1.18 g, 9.4 mmol) in CCl4 (200.6 mL) at 25-30 °C. The resulting mixture was stirred at 25-30 °C for 24 h. The progress of the reaction was monitored by TLC.
[0307] After 18 h, the reaction mixture was concentrated at 40° C. to give a crude residue. The residue was purified by CombiFlash® using ethyl acetate:hexanes as eluent to give compound B as a white solid.
[0308] Yield: 0.62g (41.3%); 1 H-NMR-DMSO-d6(400MHz):δ:3.74(3H,s),6.13-6.15(1H,m),6.76-6.78(1H,m),12.70(1H,bs);LCMS:159.85[M+H] +
[0309] Step 2: Synthesis of methyl 5-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrolecarboxylate (C) [ka] K2CO3 (0.46 g, 3.3 mmol) was added to a stirred solution of compound B (0.3 g, 1.8 mmol) in DMF (3 mL) at 25-30 °C. After 5 min, SEM-chloride (0.39 mL, 2.2 mmol) was added dropwise at 25-30 °C. The resulting mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0310] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give a crude residue. The residue was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a colorless oil.
[0311] Yield: 0.47g (86.4%) 1H-NMR-DMSO-d6(400MHz):δ:-0.09(9H,s),0.79(2H,t,J=7.6Hz),3.49(2H,t,J= 7.6Hz),3.74(3H,s),5.69(2H,s),6.33(1H,d,J=4.0Hz),6.98(1H,d,J=4.0Hz); LCMS: 312.2 [M+Na] +
[0312] Step 3: Synthesis of 5-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrole carboxylic acid (D) [ka] Lithium hydroxide monohydrate (0.16 g, 4.01 mmol) was added to a stirred solution of compound C (0.46 mg, 1.6 mmol) in MeOH:THF:water (13.8 mL, 1:1:1, 4.6 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0313] After 18 hours, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The solid was washed with hexane (5 mL) to give compound D as a white solid.
[0314] Yield: 0.42g (35.5%); 1 H-NMR-DMSO-d6(400MHz):δ:-0.08(9H,s),0.79(2H,t,J=7.6Hz),3.49(2H,t,J=7 .6Hz),5.72(2H,s),6.27(1H,d,J=4.0Hz),6.90(1H,d,J=4.0Hz),12.64(1H,bs); LCMS: 298.2 [M+Na] +
[0315] Step 4: Synthesis of ethyl (E)-2-(5-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexanoate (F) [ka] Oxalyl chloride was added to a stirred solution of compound D (0.2 g, 0.72 mmol) in DMF (4.0 mL) at 0-5° C., followed by DMF (0.08 mL). The resulting mixture was stirred at 25-30° C. for 2 h. The progress of the reaction was monitored by TLC.
[0316] After the reaction was completed, the reaction mixture was concentrated and dried at 40° C. The resulting residue was pre-dissolved in DCM (4.0 mL) and added to (E)-2-amino-5,5-dimethyl-3-hexanoate (E) (0.13 g, 0.72 mmol) at 25-30° C., followed by the addition of DIPEA (0.5 mL, 2.8 mmol). The resulting mixture was stirred at 25-30° C. for 18 h.
[0317] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution (20 mL) until pH was about 7-8, and the product was extracted with DCM (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound F as a light brown oil.
[0318] Yield: 0.228g (70.9%); 1H-NMR-DMSO-d6(400MHz):δ:-0.09(9H,s),0.76(2H,t,J=9.6Hz),0.98(9H,s),1.15(3H,t,J=9.6Hz),3.44(2H,t,J=10.4Hz),4.10(2H,q,J=9.6Hz), 4.82(2H,t,J=9.6Hz),5.45-5.53(1H,m),5.74-5.83(3H,m),6.26(1H,d,J =5.2Hz),7.01(1H,d,J=5.6Hz),8.61(1H,d,J=9.2Hz);LCMS:462.17[M+Na] +
[0319] Step 5: Synthesis of (E)-2-(5-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (G) [ka] Lithium hydroxide monohydrate (0.052 g, 1.2 mmol) was added to a stirred solution of compound F (0.22 g, 0.49 mmol) in MeOH:THF:water (6.6 mL, 1:1:1, 2.2 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0320] After completion of the reaction, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH about 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to obtain a crude solid. The resulting solid was washed with hexane (5 mL) to obtain compound G as a white sticky solid.
[0321] Yield: 0.19g (95.9%); 1H-NMR-DMSO-d6(400MHz):δ:-0.09(9H,s),0.78(2H,t,J=9.6Hz),0.98(9H,s),3.44(2H,t,J=7.6Hz),4.78(1H,t,J=6.4Hz ),5.48-5.53(1H,m),5.69-5.79(3H,m),6.23(1H,d,J=4.0Hz),6.99(1H,d,J=4.0Hz),8.40(1H,d,J=6.8Hz),12.71(1H,s); LCMS: 437.10 [M+Na] +
[0322] Step 6: Synthesis of (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (H) [ka] 4M HCl in 1,4-dioxane (3.8 mL) was added to a stirred solution of compound G (0.19 g, 0.45 mmol) in 1,4-dioxane (0.95 mL) at 25-30° C. The resulting mixture was stirred for 18 h at 25-30° C. The progress of the reaction was monitored by TLC.
[0323] After 18 h, the reaction mixture was concentrated at 40° C. to give a crude solid, which was washed with hexane (5 mL) to give a white solid (0.13 g).
[0324] Ammonium hydroxide solution (0.9 mL) was added to a crude solution of the solid material (90 mg, 0.28 mmol) in ACN (1.8 mL) at 25-30° C. The resulting mixture was stirred for 18 h at 25-30° C. The progress of the reaction was monitored by TLC.
[0325] After 18 h, the reaction mixture was concentrated at 40° C. to give a crude residue, which was washed with hexane (5 mL) to give the pure product H as a white solid.
[0326] Yield: 19.7 mg; 1H-NMR-DMSO-d6(400MHz):δ:0.97(9H,s),4.81-4.85(1H,m),5.45-5.51(1H,m),5.74-5.78(1H,m), 6.04(1H,d,J=4.0Hz),6.88(1H,d,J=4.0Hz),8.26(1H,d,J=7.8Hz);12.24(1H,bs),12.60(1H,bs); LCMS: 285.3 [M+H] + ;HPLC purity -98.4%
[0327] Example 21 Synthesis of 1-(E)-2-(4,5-dichloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI62) Step 1: Synthesis of ethyl (E)-2-(4,5-dichloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 4,5-Dichloro-2-thenoic acid (B) (103.8 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0328] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a pale yellow thick oil.
[0329] Yield: 148 mg (76.6%); 1 H-NMR-CD3OD(400MHz):δ:1.02(9H,s),1.22-1.26(3H,m),4.16-4.17(2H,m) ,4.93-4.96(1H,m),5.50-5.53(1H,m),5.86-5.90(1H,m),7.68-7.69(1H,m); LCMS: 363.97 [M+H] +
[0330] Step 2: Synthesis of (E)-2-(4,5-dichloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (40.9 mg, 0.97 mmol) was added to a stirred solution of compound C (142 mg, 0.38 mmol) in MeOH / THF / water (4.26 mL, 1:1:1, 1.42 mL each). The resulting reaction mixture was stirred at 25-30 °C for 2.5 h. The progress of the reaction was monitored by TLC.
[0331] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexane (5 mL) to give a mixture of the two as a white solid. The crude mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0332] Yield: 65mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),4.81-4.86(1H,m),5.44-5.52(1H,m ),5.84(1H,d,J=21.2Hz),8.01(1H,s),9.02(1H,d,J=9.6Hz),12.81(1H,bs); LCMS: 336.3 [M+H] +;HPLC purity -98.4%.
[0333] Example 2 Synthesis of 2-(E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI31) Step 1: Synthesis of ethyl (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 4-Chloro-1-methyl-2-pyrrolyl carboxylic acid (B) (86 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.35 mL, 2.12 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0334] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude material was purified by RP-HPLC to give pure compound C as a colorless thick oil.
[0335] Yield: 11 mg, (6.5%) LCMS: 327.5 [M+H] +
[0336] Step 2: Synthesis of (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (7 mg, 0.15 mmol) was added to a stirred solution of compound C (11 mg, 0.03 mmol) in MeOH / THF / water (0.33 mL, 1:1:1). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0337] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The solid material was washed with hexanes (5 mL) to give a crude mixture of two isomers as a white solid. The crude material was purified by RP-HPLC to give product D as a white solid.
[0338] Yield: 0.4mg LCMS: 299.2 [M+H] +
[0339] Example 2 Synthesis of 3-(E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI32) Step 1: Synthesis of ethyl (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 4-Chloro-2-thenoic acid (B) (97.26 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.35 mL, 2.12 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0340] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a brown thick oil.
[0341] Yield: 47mg (27.0%) 1 H-NMR-CD3OD(400MHz):δ:0.96(9H,s),1.26(3H,t,J=7.2Hz),4.16-4.24(2H,m),4. 96-4.98(1H,m),5.53-5.59(1H,m),5.93(1H,d,J=1.2Hz),7.56(1H,s),7.73(1H,s); LCMS: 330.3 [M+H] +
[0342] Step 2: Synthesis of (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (39.9 mg, 1.04 mmol) was added to a stirred solution of compound C (47 mg, 0.14 mmol) in THF / methanol / water (1.41 mL, 1:1:1, 0.47 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0343] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude mixture was purified by RP-HPLC to give pure compound D as a white solid.
[0344] Yield: 22mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.97(9H,s),4.76(1H,t,J=6.8Hz),5.46-5.51(1H,m),5.74(1H,d,J=16.0Hz),7.80(1H,s),7.92(1H,s),8.76(1H,bs); LCMS: 302.6 [M+H] + ;HPLC purity -99.2%.
[0345] Example 2 Synthesis of 4-(E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (SI34) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexanoate (C) [ka] p-(3-pyridyloxy)benzoic acid (A) (116 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.35 mL, 2.12 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0346] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a yellow thick oil.
[0347] Yield: 50.0 mg, (24.2%); 1 H-NMR-CD3OD(400MHz):δ:1.02(9H,s),1.24-1.31(3H,m),4.19-4.22(2H,m),5.04(1H,d,J=1.2Hz),5.61-5.62 (1H,m),5.94(1H,d,J=1.2Hz),7.11(2H,d,J=8.8Hz),7.46-7.66(2H,m),7.91-7.94(2H,m),8.37-8.38(2H,m); LCMS: 383.4 [M+H] +
[0348] Step 2: Synthesis of (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (43.9 mg, 1.04 mmol) was added to a stirred solution of compound C (80 mg, 0.20 mmol) in THF / methanol / water (2.4 mL, 1:1:1, 0.8 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0349] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude product was purified by RP-HPLC to give pure compound D as a white solid.
[0350] Yield: 3.0 mg; 1 H-NMR-DMSO-d6(300MHz):δ:1.1(9H,s),4.99(1H,t,J=7.2Hz),5.62-5.70(1H,m),5.93(1H,d,J=15.6Hz),7.21(2H, d,J=8.7Hz),7.55-7.66(2H,m),8.06(2H,d,J=8.7Hz),8.53(2H,d,J=4.2Hz),8.88(1H,d,J=7.2Hz),12.67(1H,bs); LCMS: 355.3 [M+H] + ;HPLC purity -98.9%.
[0351] Example 2 Synthesis of 5-(E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid (SI36) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexanoate (C) [ka] 2-Phenoxyisonicotinic acid (A) (116.15 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.35 mL, 2.12 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0352] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give the crude product. The crude product was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a brown thick oil.
[0353] Yield: 103 mg, (49.9%); 1 H-NMR-CD3OD(400MHz):δ:1.02(9H,s),1.23(3H,t,J=6.8Hz),4.16-4.19(2H,m),5.00(1H,d,J=1.2Hz),5.53(1H,m),5. 89(1H,d,J=1.2Hz),7.10(2H,t,J=0.8Hz),7.12(1H,d,J=0.8Hz),7.21(1H,s),7.29-7.46(3H,m),8.22(1H,d,J=0.8Hz); LCMS: 383.3 [M+H] +
[0354] Step 2: Synthesis of (E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (54 mg, 1.3 mmol) was added to a stirred solution of compound C (100 mg, 0.26 mmol) in THF / methanol / water (3.0 mL, 1:1:1, 1.0 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0355] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude mixture was purified by RP-HPLC to give pure compound D as a white solid.
[0356] Yield: 45mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.97(9H,s),4.84(1H,d,J=1.2Hz),5.54(1H,d,J=1.2Hz),7.14(2H,d,J=0.8Hz),7.20 -7.24(1H,m),7.40-7.45(3H,m),7.52-7.54(1H,d,J=1.2Hz),8.27(1H,d,J=5.2Hz),9.11(1H,bs),12.68(1H,bs); LCMS: 355.3 [M+H] + ;HPLC purity -98.4%.
[0357] Example 26 Synthesis of (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (SI39) Step 1: Synthesis of ethyl (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexanoate (C) [ka] 6-(Benzyloxy)nicotinic acid (A) (123.7 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (B) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.35 mL, 2.12 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 48 h. The progress of the reaction was monitored by TLC.
[0358] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The crude product was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a brown thick oil.
[0359] Yield: 65 mg (30.4%); 1 H-NMR-CD3OD(400MHz):δ:1.03(9H,s),1.22-1.26(3H,m),4.16-4.20(2H,m),5.01(1H,m),5.40(2H,s),5.58(2H,d,J= 7.2Hz),5.89(2H,d,J=1.2Hz),6.88(1H,m),7.31-7.35(3H,m),7.41-7.43(2H,m),8.12(1H,d,J=2.8Hz),8.66(1H,s); LCMS: 397.3 [M+H] +
[0360] Step 2: Synthesis of (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (32.8 mg, 0.78 mmol) was added to a stirred solution of compound C (62 mg, 0.15 mmol) in THF / methanol / water (1.24 mL, 1:1:1, 0.62 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0361] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude material was purified by RP-HPLC to give pure compound D as a white solid.
[0362] Yield: 16mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),4.87(1H,d,J=7.2Hz),5.40(2H,s),5.53(1H,d,J=7.2Hz),5.82(1H,d,J=1.2Hz),6. 95(1H,d,J=8.8Hz),7.3(3H,t,J=4.8Hz),7.35-7.46(2H,m),8.18(1H,d,J=2.4Hz),8.70(1H,s),8.81(1H,bs),12.66(1H,bs); LCMS: 369.3 [M+H] + ;HPLC purity 98.6%
[0363] Example 27 Synthesis of (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid (SI41) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexanoate (C) [ka] p-(2-pyrimidinyloxy)benzoic acid (B) (116.6 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0364] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a brown thick oil.
[0365] Yield: 65mg, (31.6%); 1 H-NMR-DMSO-d6(400MHz):δ:1.02(9H,s),1.16(3H,t,J=7.2Hz),4.10(2H,q,J=3.6Hz),4.88-4.92(1H,m),5.52-5.57(1H,m ),5.83-5.87(1H,m),7.28-7.31(3H,m),7.95(2H,d,J=8.4Hz),8.65-8.68(2H,m),8.91(1H,d,J=6.8Hz);LCMS:384.3[M+H] +
[0366] Step 2: Synthesis of (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (16.7 mg, 0.39 mmol) was added to a stirred solution of compound C (61 mg, 0.15 mmol) in THF:water (1.83 mL, 2:1). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0367] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as a white solid. The crude solid was purified by RP-HPLC to give the pure product D as a white solid.
[0368] Yield: 20.0 mg; 1 H-NMR-DMSO-d6(400MHz):δ:1.02(9H,s),4.87-4.91(1H,m),5.53-5.59(1H,m),5.80-5.85(1H,m), 7.28-7.30(3H,m),7.95(2H,d,J=8.4Hz),8.65-8.68(2H,m),8.81(1H,d,J=7.2Hz),12.64(1H,bs); LCMS: 356.03 [M+H] + ;HPLC purity -99.8%.
[0369] Example 28: Synthesis of (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid (SI44) Step 1: Synthesis of ethyl 2-phenoxy-5-pyrimidinecarboxylate (B) [ka] K2CO3 (1.1 g, 8.02 mmol) was added to a stirred solution of ethyl 2-chloro-5-pyrimidinecarboxylate (A) (1 g, 5.35 mmol) and phenol (0.55 g, 5.89 mmol) in DMF (20 mL) at 25-30 °C. The resulting reaction mixture was stirred at 60 °C for 2 h. The progress of the reaction was monitored by TLC.
[0370] After completion of the reaction, the reaction mixture was quenched by adding ice-cold water and the product was extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuum at 40° C. to give a crude residue. The crude residue was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound B as a colorless thick oil.
[0371] Yield: 1.1g (84.6%). 1 H-NMR-DMSO-d6(400MHz):δ:1.30(3H,t,J=7.2Hz),4.30(2H,q,J=7.2Hz),7.23-7.30(3H,m),7.44-7.48(2H,m),9.06(2H,m); LCMS: 245.1 [M+H] +
[0372] Step 2: Synthesis of 2-phenoxy-5-pyrimidinecarboxylic acid (C) [ka] 1M NaOH aqueous solution (0.98 mL, 0.9 mmol) was added to a stirred solution of compound B (0.2 g, 0.81 mmol) in THF (2 mL) at 0-5° C. The resulting reaction mixture was stirred at 25-30° C. for 4 h. The progress of the reaction was monitored by TLC.
[0373] After 4 hours, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The crude solid was washed with hexane (5 mL) to give compound C as a white solid.
[0374] Yield: 0.14g (83.4%). 1 H-NMR-DMSO-d6(400MHz):δ:7.23-7.31(3H,m),7.43-7.48(2H,m),9.03(2H,m),13.76(1H,bs);LCMS:216.88[M+H] +
[0375] Step 3: Synthesis of ethyl (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexanoate (E) [ka] Compound C (116.6 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (D) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0376] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give a crude residue. The crude residue was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound E as a pale green thick oil.
[0377] Yield: 75 mg (43.6%); 1 H-NMR-DMSO-d6(400MHz):δ:1.02(9H,s),1.32(3H,t,J=7.6Hz),4.13(2H,q,J=7.2Hz),4.93-4.96(1H,m),5. 47-5.55(1H,m),5.86-5.91(1H,m),7.23-7.41(3H,m),7.44-7.49(2H,m),9.04(2H,s),9.15(1H,d,J=8.8Hz); LCMS: 384.3 [M+H] +
[0378] Step 4: Synthesis of (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid (F) [ka] 1M NaOH aqueous solution (0.21 mL, 0.21 mmol) was added to a stirred solution of compound E (70 mg, 0.18 mmol) in THF (0.7 mL) at 0-5° C. The resulting reaction mixture was stirred at 25-30° C. for 2 h. The progress of the reaction was monitored by TLC.
[0379] After 2 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using saturated potassium hydrogen sulfate solution and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The solid was washed with hexane (5 mL) to give a white solid. The crude solid was purified by RP-HPLC to give the pure product F as a white solid.
[0380] Yield: 19 mg; 1H-NMR-DMSO-d6(400MHz):δ:1.02(9H,s),4.82-4.93(1H,m),5.49-5.55(1H,m),5.81- 5.85(1H,m),7.22-7.29(3H,m),7.43-7.47(2H,m),9.03-9.05(3H,m),12.39(1H,bs); LCMS: 356.07 [M+H] + ;HPLC purity -98.9%.
[0381] Example 29: Synthesis of (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI53) Step 1: Synthesis of ethyl (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexanoate (C) [ka] p-(p-Chlorophenoxy)benzoic acid (B) (131.7 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0382] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude product. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a pale yellow thick oil.
[0383] Yield: 35 mg (15.8%); 1H-NMR-CD3OD(400MHz):δ:1.02(9H,s),1.24(3H,t,J=7.2Hz),4.17(2H,d,J=5.2Hz),5.02-5.04(1H ,m),5.58-5.60(1H,m),5.87-5.91(1H,m),7.00-7.04(4H,m),7.36-7.39(2H,m),7.85-7.87(2H,m); LCMS: 416.13 [M+H] +
[0384] Step 2: Synthesis of (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (7.56 mg, 0.18 mmol) was added to a stirred solution of compound C (30 mg, 0.07 mmol) in MeOH / THF / water (0.9 mL, 1:1:1, 0.3 mL each). The resulting reaction mixture was stirred at 25-30 °C for 7 h. The progress of the reaction was monitored by TLC.
[0385] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using 1.5 N HCl and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give the crude product as a white solid. The crude material was purified by RP-HPLC to give product D as a white solid.
[0386] Yield: 10mg; 1H-NMR-DMSO-d6(400MHz):δ:1.00(9H,s),4.84-4.88(1H,m),5.52-5.59(1H,m),5.81(1H,d,J=20.8Hz), 7.06-7.13(4H,m),7.48(2H,d,J=12.0Hz),7.94(2H,d,J=11.6Hz),8.70(1H,d,J=9.2Hz),12.67(1H,bs); LCMS: 388.10 [M+H] + ;HPLC purity -96.5%.
[0387] Example 30 - Synthesis of (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (SI54) Step 1: Synthesis of ethyl (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexanoate (C) [ka] p-(m-Chlorophenoxy)benzoic acid (B) (100 mg, 0.40 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (74.50 mg, 0.40 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.28 mL, 1.60 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.76 mL, 1.2 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0388] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a pale yellow thick oil.
[0389] Yield: 29 mg (17.3%); 1 H-NMR-CD3OD(400MHz):δ:0.96(9H,s),1.22-1.28(3H,m),4.17-4.20(2H,m),4.99-5.01(1H,m),5.57( 1H,t,J=7.6Hz),5.90(1H,d,J=1.2Hz),7.03-7.06(5H,m),7.35(1H,d,J=8.0Hz),7.87(2H,t,J=1.2Hz); LCMS: 416.4 [M+H] +
[0390] Step 2: Synthesis of (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (6.30 mg, 0.15 mmol) was added to a stirred solution of compound C in MeOH / THF / water (0.75 mL, 1:1:1, 0.25 mL each). The resulting reaction mixture was stirred at 25-30° C. for 18 h. The progress of the reaction was monitored by TLC.
[0391] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and acidified to pH 4-5 using 1.5 N HCl at 0-5 °C, and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as a white solid. The crude product was purified by RP-HPLC to give the pure product D as a white solid.
[0392] Yield: 8.4 mg; 1H-NMR-DMSO-d6(400MHz):δ:0.97(9H,s),5.50-5.56(1H,m),5.77-5.81(1H,m),7.01-7.09(1H, m),7.10-7.14(3H,m),7.22-7.25(1H,m),7.42(1H,t,J=8.0Hz),7.92-7.94(2H,m),8.8(1H,bs); LCMS: 388.5 [M+H] + ;HPLC purity: 97.9%.
[0393] Example 3 Synthesis of 1-(E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid (SI55) Step 1: Synthesis of ethyl (E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexanoate (C) [ka] p-(Phenoxymethyl)benzoic acid (B) (120 mg, 0.64 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (147.83 mg, 0.64 mmol) in DMF (3.0 mL) at 25-30 °C, followed by DIPEA (0.45 mL, 2.59 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.23 mL, 1.94 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0394] After the reaction was completed, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give pure compound C as a brown thick oil.
[0395] Yield: 34mg (13.3%)
[0396] Step 2: Synthesis of (E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (8.73 mg, 0.20 mmol) was added to a stirred solution of compound C (32 mg, 0.08 mmol) in MeOH / THF / water (0.96 mL, 1:1:1, 0.32 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0397] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and acidified to pH 4-5 using 1.5 N HCl at 0-5° C., and the product was extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a solid material. The solid material was washed with hexanes (5 mL) to give a crude mixture of two isomers as a white solid. The crude mixture was purified by RP-HPLC to give the pure product D as a pure white solid.
[0398] Yield: 12.5 mg; 1 H-NMR-CDCl3(400MHz):δ:1.00(9H,s),4.86-4.90(1H,m),5.18(2H,s),5.53-5.59(1H,m),5.81(1H,d,J= 1.2Hz),6.92-7.02(3H,m),7.27-7.31(2H,m),7.53(2H,d,J=8.4Hz),7.91(2H,d,J=8.4Hz),8.79(1H,s); LCMS: 368.3 [M+H] + ;HPLC purity 99.0%.
[0399] Example 3 Synthesis of 2-(E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI56) Step 1: Synthesis of ethyl (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 1-Ethyl-3-isobutyl-5-pyrazole carboxylic acid (B) (105.7 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.376 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.028 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0400] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a thick yellow liquid.
[0401] Yield: 47 mg, (24.0%); 1 H-NMR-DMSO-d6(400MHz):δ:0.94-0.97(6H,m),1.05(9H,s),1.23-1.36(6H,m),1.90-1.95(1H,m),2.48(2H,d,J=7.2 Hz),4.16-4.24(2H,m),4.43-4.48(2H,m),4.96(1H,d,J=7.2Hz),5.54-5.59(1H,m),5.88-5.92(1H,m),6.66(1H,s); LCMS-363.49[M+H] +
[0402] Step 2: Synthesis of (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (27.15 mg, 0.64 mmol) was added to a stirred solution of compound C (47 mg, 0.12 mmol) in THF / methanol / water (1.41 mL, 1:1:1, 0.47 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0403] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0404] Yield: 28.9 mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.90-0.88(6H,m),0.99(9H,s),1.23(3H,t,J=6.8Hz),1.83-1.86(1H,m),2.49(2H,d,J=2.0Hz), 4.34-4.41(2H,m),4.80-4.82(1H,m),5.33-5.45(1H,m),5.79-5.83(1H,m),6.74(1H,s)8.67(1H,d,J=7.2Hz),12.6(1H,bs); LCMS: 336.4 [M+H] + ;HPLC purity -99.2%.
[0405] Example 3 Synthesis of 3-(E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI57) Step 1: Synthesis of ethyl (E)-2-(3-chloro-1-methyl-5-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 3-Chloro-1-methyl-5-pyrazole carboxylic acid (B) (86.53 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.376 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.02 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0406] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35 °C to give a crude residue. The crude residue was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a thick yellow liquid.
[0407] Yield: 52 mg, (29.4%); 1 H-NMR-CD3OD(300MHz):δ:1.06(9H,s),1.25-1.35(3H,m),4.04(3H,s),4.15-4.25 (2H,m),4.97(1H,d,J=7.5Hz),5.50-5.58(1H,m),5.88-5.94(1H,m),6.83(1H,s); LCMS: 328.3 [M+H] +
[0408] Step 2: Synthesis of (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (33.3 mg, 0.79 mmol) was added to a stirred solution of compound C (52 mg, 0.15 mmol) in THF / methanol / water (1.56 mL, 1:1:1, 0.52 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0409] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0410] Yield: 28.5 mg; 1 H-NMR-DMSO-d6(400MHz):δ:0.97(9H,s),3.96(3H,s),4.80-4.84(1H,m),5.45-5.50(1H,m),5.77-5.81(1H,m),7.02(1H,s),8.84(1H,d,J=7.6Hz); LCMS: 300.3 [M+H] + ;HPLC purity -98.4%
[0411] Example 3 Synthesis of 4-(E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (SI58) Step 1: Synthesis of ethyl (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexanoate (C) [ka] 3-Isopropyl-1-methyl-5-pyrazole carboxylic acid (B) (90.7 mg, 0.53 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (A) (100 mg, 0.53 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.37 mL, 2.15 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (1.03 mL, 1.61 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0412] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo at 35°C to give a crude residue. The crude residue was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound C as a brown thick oil.
[0413] Yield: 56 mg, (31.0%); 1 H-NMR-CD3OD(400MHz):δ:1.05(9H,s),1.25-1.28(9H,m),2.90-2.97(1H,m),4.02(3H,s),4.2 3(2H,q,J=3.6Hz),4.95-4.98(1H,m),5.53-5.58(1H,m),5.92(1H,d,J=14.4Hz),6.73(1H,s); LCMS: 366.5 [M+H] +
[0414] Step 2: Synthesis of (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid (D) [ka] Lithium hydroxide monohydrate (32.5 mg, 0.77 mmol) was added to a stirred solution of compound C (52 mg, 0.15 mmol) in THF / methanol / water (1.56 mL, 1:1:1, 0.52 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0415] After 18 h, the reaction mixture was concentrated and the residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude solid was washed with hexane (5 mL) to give a crude mixture of two isomers as a white solid. The mixture was purified by RP-HPLC to give the pure product D as a white solid.
[0416] Yield: 23 mg; 1 H-NMR-DMSO-d6(400MHz):δ:1.0(9H,s),1.19(6H,d,J=9.2Hz),2.84-2.89(1H,m),3.95(3H,s),4.81(1H,t ,J=9.6Hz),5.47-5.54(1H,m),5.82(1H,d,J=16.4Hz),6.84(1H,s),8.68(1H,d,J=9.6Hz),12.66(1H,bs); LCMS: 308.4 [M+H] + ;HPLC purity -99.4%.
[0417] Example 3 Synthesis of 5-(E)-5,5-dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid (SI59) Step 1: Synthesis of ethyl nicotinoylacetate (C) [ka] Diethyl oxalate (B) (6.7 g, 0.049 mmol) was washed with dry THF (4.5 mL) and added to a stirred solution of NaH (60% w / w, 2.95 g, 0.074 mmol) in dry THF (51 mL). The resulting mixture was heated to 75 °C, then a solution of 1-(3-pyridyl)-1-ethanone (A) (3 g, 0.024 mmol) in dry THF (4.5 mL) was added slowly with stirring at reflux. The resulting reaction mixture was stirred at 25-30 °C for 15 min. The progress of the reaction was monitored by TLC.
[0418] The resulting reaction mixture was slowly added to ice-cold 1.5N HCl solution, followed by solid NaHCO3 until slightly basic. The resulting mixture was extracted with ethyl acetate (2 x 75 mL). The combined organic layers were washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The resulting solid was dissolved in hot ethanol (100 mL) and 1 g of charcoal was added. After 5 minutes, the solution was hot filtered through a bed of Celite. The filtrate was concentrated under vacuum to give compound C as a red-brown solid.
[0419] Yield: 890mg, 16.3% yield
[0420] Step 2: Synthesis of ethyl 1-methyl-3-(3-pyridyl)-5-pyrazolecarboxylate (D) [ka] Methylhydrazine (0.118 mL) was added to a stirred solution of compound C (450 mg, 2.034 mmol) in ethanol (5.4 mL), followed by p-toluenesulfonic acid (PTSA) (699.69 mg, 4.06 mmol). The resulting reaction mixture was stirred at 80° C. for 18 h. The progress of the reaction was monitored by TLC.
[0421] After completion of the reaction, the reaction mixture was quenched by adding saturated NaHCO3 solution, and the product was extracted into ethyl acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuum at 35 °C to obtain crude material. The crude material was purified by CombiFlash® to obtain compound D as an off-white solid.
[0422] Yield: 43 mg (9.2%); 1 H-NMR-CDCl3(400MHz):δ:1.42(3H,t,J=7.2Hz),4.25(3H,s),4.39(2H,q,J=7.2Hz), 7.17(1H,s),7.34-7.37(1H,m),8.11-8.14(1H,m),8.57(1H,d,J=4Hz),9.03(1H,s); LCMS: 232.1 [M+H] +
[0423] Step 3: Synthesis of 1-methyl-3-(3-pyridyl)-5-pyrazole carboxylic acid (E) [ka] A stirred solution of compound D (34 mg, 0.14 mmol) in 1,4-dioxane (0.24 mL) was cooled to 0° C. NaOH (14.7 mg, 0.36 mmol) was dissolved in water (0.04 mL) and added dropwise to the above solution. The resulting reaction mixture was stirred at 25-30° C. for 2 h. The progress of the reaction was monitored by TLC.
[0424] After completion of the reaction, the reaction mixture was quenched by adding 1.5N HCl solution until the pH was about 2 to 3. The reaction mixture was concentrated in vacuum at 45° C. and stripped with toluene to give crude compound E as a white solid.
[0425] Yield: 50 mg (crude): 1H-NMR-DMSO-d6(300MHz):δ:4.16(3H,s),7.55(1H,s),7.73-7.77(1H,m),8.56 (1H,d,J=8.4Hz),8.67(1H,d,J=5.1Hz),9.18(1H,d,J=2.0Hz),13.65(1H,bs); LCMS: 204.0 [M+H] +
[0426] Step 4: Synthesis of ethyl (E)-5,5-dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexanoate (G) [ka] Compound E (54.65 mg, 0.26 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (F) (50 mg, 0.26 mmol) in DMF (2.5 mL) at 25-30 °C, followed by DIPEA (0.18 mL, 1.07 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.51 mL, 0.80 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0427] After the reaction was completed, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted into ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to obtain the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to obtain compound G as a white solid.
[0428] Yield: 15mg, (7.5%); H-NMR-DMSO-d6(400MHz):δ:1.01(9H,s),1.15-1.17(3H,m),4.08(3H,s),4.11-4.16(2H,m),4.86-4.90(1H,m),5.47-5.51 (1H,m),5.86-5.90(1H,m),7.40-7.45(2H,m),8.12(1H,d,J=8.0Hz),8.53(1H,d,J=2Hz),8.96(1H,s),9.00-9.02(1H,m),; LCMS: 383.3 [M+H] +
[0429] Step 5: Synthesis of (E)-5,5-dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid (H) [ka] Lithium hydroxide monohydrate (8.58 mg, 0.20 mmol) was added to a stirred solution of compound G (15 mg, 0.040 mmol) in THF / methanol / water (0.45 mL, 1:1:1, 0.15 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0430] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH ∼5-6 using 1.5 N HCl and the product was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The resulting solid was washed with hexanes (5 mL) to give a crude mixture of two isomers as an off-white solid. The crude mixture was purified by RP-HPLC to give the pure product H as a white solid.
[0431] Yield: 7.1 mg; 1H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),4.08(3H,s),4.77-4.81(1H,m),5.50-5.55(1H,m),5.79(1H,d,J= 16Hz),8.11-8.13(1H,m),8.14(1H,s),8.51-8.53(1H,m),8.71(1H,bs),8.97-8.99(1H,m),12.87(1H,bs); LCMS: 343.2 [M+H] + ;HPLC purity -99.4%.
[0432] Example 3 Synthesis of 6-(E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (SI61) Step 1: Synthesis of methyl 5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolecarboxylate (B) [ka] Methylhydrazine (50.0 mg, 1.01 mmol) was added to a stirred solution of methyl 4-(3,4-dichlorophenyl)-2,4-dioxobutyrate (A) (300 mg, 1.01 mmol) in MeOH (3.0 mL) at 25-30 °C. The resulting reaction mixture was heated at 70 °C for 2 h and stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0433] After completion of the reaction, the reaction mixture was evaporated to give a crude material containing two isomeric products. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound B as an off-white solid.
[0434] Yield: 0.11g; Int-2.2: 1 H-NMR-DMS0-d6(400MHz):δ:3.78(3H,s),3.92(3H,s),7.00(1H,s),7.58(1H,d,J=2.0Hz),7.76(1H,d,J=8.4Hz),7.89(1H,s); LCMS: 284.93 [M+H] +
[0435] Step 2: Synthesis of 5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolecarboxylic acid (C) [ka] Sodium hydroxide (61.72 mg, 1.54 mmol) was added to a stirred solution of compound B (2.2) (110 mg, 0.38 mmol) in MeOH:water (8.8 mL, 1:1, 4.4 mL each). The resulting reaction mixture was stirred at 75° C. for 4 h. The progress of the reaction was monitored by TLC.
[0436] After completion of the reaction, most of the methanol was evaporated. The aqueous mixture was acidified to pH approx. 3-4 using 1.5N HCl and the product was extracted with ethyl acetate (3×10 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40° C. to give a crude solid. The solid was washed with hexane (15 mL) to give crude compound C as a white solid. The crude material was used as is in the next reaction.
[0437] Yield: 99 mg (crude); 1 H-NMR-DMSO-d6(400MHz):δ:3.90(3H,s),6.92(1H,s),7.56(1H,d,J=2.0Hz),7.75(1H,d,J=8.4Hz),7.88(1H,s),12.74(1H.bs); LCMS: 270.91 [M+H] +
[0438] Step 3: Synthesis of ethyl (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexanoate (E) [ka] Compound C (95 mg, 0.35 mmol) was added to a stirred solution of (E)-2-amino-5,5-dimethyl-3-hexanoate (D) (64.9 mg, 0.40 mmol) in DMF (2.37 mL) at 25-30 °C, followed by DIPEA (0.24 mL, 1.40 mmol) and propylphosphonic anhydride (T3P, ca. 50% solution in ethyl acetate) (0.66 mL, 1.05 mmol). The resulting reaction mixture was stirred at 40 °C for 18 h. The progress of the reaction was monitored by TLC.
[0439] After completion of the reaction, the reaction mixture was quenched with saturated NaHCO3 solution until pH was about 7-8, and the product was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum at 35°C to give the crude material. The crude material was purified by CombiFlash® using ethyl acetate:hexane as eluent to give compound E as a brown thick oil.
[0440] Yield: 60mg 39.0%; 1 H-NMR-CD3OD(300MHz):δ:0.99(9H,s),1.28(3H,t,J=6.9Hz),3.96(3H,s),4.20-4.27(2H,m),5.07(1H,d,J=6.0Hz) ,5.56-5.63(1H,m),5.91(1H,d,J=15.6Hz),6.87(1H,s),7.48(1H,d,J=1.2Hz),7.68(1H,d,J=8.4Hz),7.75(1H,s); LCMS: 438.5 [M+H] +
[0441] Step 4: Synthesis of (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid (F) [ka] Lithium hydroxide monohydrate (13.16 mg, 0.31 mmol) was added to a stirred solution of compound E (4.2) (55 mg, 0.12 mmol) in MeOH / THF / water (1.65 mL, 1:1:1, 0.55 mL each). The resulting reaction mixture was stirred at 25-30 °C for 18 h. The progress of the reaction was monitored by TLC.
[0442] After 18 h, the reaction mixture was concentrated and the resulting residue was dissolved in water and washed with diethyl ether (10 mL). The aqueous layer was acidified to pH 4-5 using 1.5 N HCl at 0-5 °C and the product was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over sodium sulfate and concentrated at 40 °C to give a crude solid. The crude solid was purified by RP-HPLC to give the pure product F as a white solid.
[0443] Yield: 42mg (81.6%); 1 H-NMR-DMSO-d6(400MHz):δ:0.99(9H,s),3.94(3H,s),4.87(1H,t,J=6.9Hz),5.58(1H,d,J=6.9Hz,5.77(1H,d,J=15 .6Hz),6.92(1H,s),7.60(1H,d,J=8.1Hz),7.79(1H,d,J=8.4Hz),7.91(1H,s),8.17(1H,d,J=7.5Hz),12.78(1H,bs); LCMS: 410.3 [M+H] + ;HPLC purity -98.6%.
[0444] Example 37 - Synthesis of S10 to S12, S14 to S15, SI18 to SI22, SI26 to SI27, SI30, SI33, SI35, SI37 to SI38, SI40, SI42 to SI43, SI45 to SI48, and SI63 to S84 These compounds were prepared in the same manner as described above for Example 5, starting from the coupling of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate with the appropriate commercially available aromatic, heteroaromatic or heterocyclic carboxylic acid, followed by hydrolysis of the resulting ethyl ester to give the expected product.
[0445] Example 38 - Synthesis of 2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethylhexanoic acid (Reference Compound 1 (RC1)) [ka] 2-Hydroxypyridine-1-oxide (26 mg, 0.276 mmol) and N,N'-diisopropylcarbodiimide (35 mg, 0.276 mmol) were added to a solution of 2-(dimethylamino)-4-methyl-5-pyrimidinecarboxylic acid (B) (50 mg, 0.276 mmol) in DMSO (1 mL) and the reaction mixture was stirred at 0 °C for 10 min. A preformed solution of (S)-2-amino-5,5-dimethylhexanoic acid (A) (44 mg, 0.276 mmol) in acetonitrile:water (1:1, 0.5 mL) was added and the mixture was stirred at room temperature for 4 h. The crude material was purified by reverse phase HPLC (C18 column, gradient of 5-100% MeCN / H2O with 0.05% HCOOH). The solvent was evaporated by lyophilization to give pure compound C.
[0446] Yield: 6.0mg (6.7%) 1 H NMR(400MHz,DMSO-d6)δ:8.35(s,1H),8.30(d,J3=7.7Hz,1H),4.25-4.13(m,1H) ),3.14(s,6H),2.41(s,3H),1.82-1.57(m,2H),1.34-1.16(m,2H),0.86(s,9H).
[0447] Example 39 Synthesis of (S)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)hexanoic acid (RC2) [ka] This compound was prepared as described in the supplementary data of the paper by Shawn J Stachel et al., Bioorganic & Medicinal Chemistry Letters (2020), 30(17):127403.
[0448] Example 40 Synthesis of 2-(N-6-methyl-2-pyridylcarbamoyl)-5-(trifluoromethyl)benzoic acid (RC3) [ka] This compound was prepared as described in WO2014 / 114779.
[0449] Example 41 - Binding of compounds to sortilin using a neurotensin competitive fluorescence polarization binding assay (FPA) Materials and Methods Synthesis of secreted sortilin (sSORT) and neurotensin The extracellular portion of human sortilin (NCBI Reference Sequence: NM_002959.7), amino acids 1-756 of SEQ ID NO:1 and a C-terminal His6 tag, was produced in CHO-S cells by transient transfection as a secreted protein. Supernatants from two different transfection reagents (150 ml of FectoPro and 150 ml of NovaCHOice) were pooled. Purification was performed by using immobilized metal ion affinity chromatography (IMAC) in buffer (50 mM HEPES pH 7.4, 100 mM NaCl and 2 mM CaCl2). The protein was eluted using an imidazole gradient (125-500 mM), fractions containing sSORT were pooled and the size of the protein was confirmed by Western blot. The buffer was exchanged to 50 mM HEPES, pH 7.4; 100 mM NaCl; 2.0 mM CaCl2 and stored at -80°C. Neurotensin, amino acid sequence LYENKPRRPYIL, SEQ ID NO:4 (Genescript), and neurotensin-Ahx-FITC (Genescript), which contains the same sequence with the additional N-terminal modification FITC-Ahx, were used as competitive ligands for sSORT.
[0450] Fluorescence polarization assay conditions Fresh 0.1% bovine serum albumin (BSA) was added to the assay buffer to obtain the final concentrations: 50 mM HEPES, pH 7.4; 100 mM NaCl; 2.0 mM CaCl2; 0.1% BSA; 0.1% TWEEN® 20. The sortilin inhibitors of the present invention and reference compounds analyzed in the screen (see Table 1) as well as neurotensin (used as an assay control) were serially diluted to 10 different concentrations in assay buffer. In each well of a Nunc® MaxiSorp™ 384-well plate (Sigma Aldrich), 100 nM sSORT was mixed with pre-diluted sortilin inhibitors and 10 nM neurotensin-Ahx-FITC in assay buffer adjusted to contain 1% DMSO in a final volume of 20 μl. The plate was then briefly centrifuged and then incubated at room temperature in the dark for 1 hour. mPolarization values were obtained by flashing each well 200 times from a CLARIOstar plate reader (excitation 482 nm, emission 530-540 nm). Z' values were calculated from a total of 16 positive and 16 negative controls.
[0451] result To demonstrate the binding of sortilin inhibitors to sortilin, a competitive binding assay of sortilin was performed using a fluorescence polarization-based (FPA) method with neurotensin as a competing ligand (Figure 1A-S). Mean IC 50 The values are shown in Table 1. All compounds in Table 1, except SI1, SI5 and RC2, were tested only as the racemate. [Table 1] TIFF2024542806000199.tif28159
[0452] As can be seen by comparing sortilin inhibitor SI5 of the invention with reference compound RC2 and sortilin inhibitor SI1 of the invention with reference compound RC1, sortilin inhibitors of the invention having unsaturated aliphatic moieties instead of the saturated aliphatic moieties of the reference compounds have a mean IC 50The values are lower, thereby indicating a higher binding affinity for sortilin, which is even more pronounced when comparing the pure enantiomers SI5 and RC2.
[0453] Example 42 - Progranulin-induced secondary sphere formation and reduction in baseline sphere formation in MDA-MB-231 breast cancer cell line, HT-29 colon cancer cell line, and SK-MEL-30 melanoma cell line Materials and Methods Peptide Therapy C-Terminal Progranulin (Progranulin) (Caslo, peptide sequence: EAPRWDAPLRDPALRQL, SEQ ID NO: 5) was reconstituted in sterile PBS upon delivery, aliquoted and stored at -20°C. Working stock concentrations were achieved by dilution with culture medium. MDA-MB-231, HT-29 or SK-MEL-30 cell lines were treated with or without 500 nM Progranulin and with or without the indicated concentrations of sortilin inhibitors of the present invention SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62 or RC3 (AF38469, Bioorganic & Medicinal Chemistry Letters, 2014, 24(1):177-180) at 37°C, 5% CO2 and 21% O2 for 48 hours, followed by primary sphere formation and subsequent secondary sphere formation assays.
[0454] Second generation sphere formation Sphere formation assay was performed as previously described (Mammary Gland Biol Neoplasia, 2012, 17(2):111-117). Briefly, single cell suspensions were obtained after treatment with each of the sortilin inhibitors of the present invention, SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62, and plated in phenol red-free DMEM / F-12 (Gibco®, Life Technologies) supplemented with 1% B27 supplement (Fisher Scientific, Invitrogen), 1% P / S and 20 ng / ml EGF (BD Biosciences) on non-adherent poly-hema coated plates. After 5 days of culture, single cell suspensions were obtained from primary spheres and plated again in phenol red-free DMEM / F-12 supplemented with 1% B27 supplement, 1% P / S and 20 ng / ml EGF on non-adherent poly-hema coated plates for 5-7 days. Spheres larger than 50 μm in diameter were then counted manually under a microscope.
[0455] result To determine whether the increase in sphere formation caused by Progranulin could be blocked using the sortilin inhibitors SI1, SI5 and SI8 of the present invention, the triple-negative breast cancer cell line MDA-MB-231 was treated with Progranulin alone, or in combination with the sortilin inhibitors SI1, SI5 and SI8 of the present invention, or with the published sortilin-binding small molecule RC3 (Breast Cancer Research 2018 20:137). The results show that, as expected, Progranulin increased secondary sphere formation (Figure 2A-D). Furthermore, the combination of Progranulin and RC3 reduced sphere formation (Figure 2A). However, RC3 has agonistic properties even when not used in combination with Progranulin, as shown by the increased sphere formation with the use of RC3 alone (Figure 3A). The sortilin inhibitors SI1, SI5 and SI8 of the present invention demonstrated reduced sphere formation in combination with Progranulin (FIG. 2B-D) without agonistic properties when used alone (FIG. 3B-D). Favorable antagonistic properties were also demonstrated with SI25, SI32, SI39, SI51 and SI62 (FIG. 3E-I). In contrast to RC3, SI1, SI5, SI8, SI25, SI32, SI39, SI51 and SI62 reduced baseline sphere formation, suggesting potent sortilin antagonistic properties. Importantly, cell viability was not affected by the compounds (FIG. 4A-I).
[0456] In addition to breast cancer, sphere formation ability was investigated using colon cancer cell line HT-29 and melanoma cell line SK-MEL-30. As shown in Figures 5 and 6, sphere formation is decreased by SI5 and SI62, respectively.
[0457] Example 43 - Increase in metastasis formation by reference compound RC3 and decrease in metastasis formation by SI5 in an MDA-MB-231 xenograft in vivo model Materials and Methods In vivo experiments Luciferase-tagged MDA-MB-231 cells were injected into two sites in the flank of NOD SCID gamma mice (Taconic, Denmark) at 0.2 × 10 6 The cells were injected subcutaneously at a cell concentration of 0.01 mg / mL. Cells were prepared in a 60% mixture of Matrigel (reduced growth factors, BD Bioscience) and 40% complete medium. Tumor size was determined by measuring the subcutaneous tumor mass with a caliper twice a week, and tumor volume was calculated as volume = (length × (width) 2 The metastasis was calculated according to the formula: γ / 2. Evaluation of metastasis was performed using an IVIS® whole body imaging device (PerkinElmer) based on luciferase expression from stably transfected cell lines. For sortilin inhibition experiments, mice were given vehicle (DMSO) or 5–50 μg RC3 (MedChem Express) / day / mouse in their drinking water supplemented weekly for 21 days, after which evaluation of metastasis was performed.
[0458] result The agonistic properties of RC3 observed in the sphere assay of Example 42 (Figure 3A) were also observed in vivo, where it induced lung metastases in the MDA-MB-231 xenograft model (Figure 7). This should be compared with the sortilin inhibitor SI5 of the present invention, which led to a reduction in metastasis formation compared to the vehicle control (Figure 8). Moreover, in Example 42, SI5, as well as SI1 and SI8, did not induce such an agonistic effect on sphere formation (Figures 3B-D).
[0459] Example 44 - Sequence information SEQ ID NO:1 MERPWGAADGLSRWPHGLGLLLLLQLLPPSTLSQDRLDAPPPPAAPLPRWSGPIGVSWGLRAAAAGGAFPRGGRWRRSAPGEDEECGRVRDFVAKLANNTHQHVFDDLRGSVSLSWVGDSTGVILVLTTFHVPLVIMTFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNF VQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGGFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYI TSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNAVGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKML EGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAH STDPEDYEDGCILGYKEQFLLRLRKSSVCQNGRDYVVTKQPSICLCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGV NPVREVKDLKKKCTSNFLSPEKQNSKSNSVPIILAIVGLMLVTVVAGVLIVKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE
[0460] SEQ ID NO:2 TFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGG RFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYITSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNA VGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKMLEGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAHSTDPEDYEDGCILGYKEQFLRLRKSSVCQNGRDY VVTKQPSILCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGVNPVREVKDLKKKCTSNFLSPEKQNSKSNSVPIILAIVGLMLVTVVAGVLIVKKYVCGGRFLVHRYSVLQQHAEANGVDGVDALDTASHTNKSGYHDDSDEDLLE
[0461] SEQ ID NO:3 MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWG CCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTC CRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGC DQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQLL
[0462] SEQ ID NO:4 LYENKPRRPYIL
[0463] SEQ ID NO:5 EAPRWDAPLRDPALRQL
[0464] The above-described embodiments should be understood as some illustrative examples of the present invention. Those skilled in the art will understand that various modifications, combinations and changes can be made to the present embodiments without departing from the spirit of the present invention. In particular, different part solutions in different embodiments can be combined in other configurations, where technically possible. However, the scope of the present invention is defined by the appended claims.
Claims
1. Compounds of Formula I: 【Chemistry 1】 (In the formula, A is a 5- or 6-membered aromatic ring, aromatic heterocycle or heterocycle having 0-2 heteroatom(s) selected from among N, O and S, or an 8-10-membered bicyclic or heteroaromatic ring having 1 or 2 heteroatom(s) selected from among N, O and S, and said aromatic ring, aromatic heterocycle, heterocyclic ring or bicyclic ring A is optionally selected from C 1 ~C 4 Alkyl, -NR 1 R 2 , -C(O)CZ 3 , -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; Y is absent, —O—, —OCH 2 --, --CH 2 --, --NR 3 - or -CH(NH 2 ) - and B is a 5- or 6-membered aromatic or heteroaromatic ring having zero or zero to four heteroatom(s) selected from among N, O and S, said aromatic or heteroaromatic ring B being optionally selected from C 1 ~C 4 Alkyl, -NR 1 R 2 , -C(O)CZ 3 , -OR 4 , substituted with one or more substituents independently selected from the group consisting of halogen and =O; R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1 ~C 4 is alkyl, Z is a halogen; R 5 is hydroxyl or C 1 ~C 4 alkoxy), or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
2. A is a 5- or 6-membered aromatic ring, heteroaromatic ring or heterocyclic ring having 0-2 heteroatom(s) selected from among N and O, preferably N, or a 9-membered bicyclic heterocycle having 1 or 2 heteroatom(s) selected from among N and O, preferably N, and said aromatic ring, heteroaromatic ring, heterocyclic ring or bicyclic ring A is optionally selected from C 1 ~C 4 Alkyl, -NR 1 R 2 , -C(O)CZ 3 , -OR 4 2. The compound of claim 1, substituted with one or more substituents independently selected from the group consisting of: , halogen, and =O.
3. The aromatic ring, the heteroaromatic ring, the heterocycle or the bicyclic ring A is optionally -CH 3 , -CH 2 CH (CH 3 ) 2 , -C(CH 3 ) 3 , -N(CH 3 ) 2 , -C(O)CZ 3 3. The compound of claim 1 or 2, substituted with one or more substituents independently selected from the group consisting of:
4. The aromatic ring, the heteroaromatic ring, the heterocycle or the bicyclic ring A is optionally -CH 3 , -CH 2 CH (CH 3 ) 2 , -C(CH 3 ) 3 , -N(CH 3 ) 2 , -C(O)CF 3 4. The compound of claim 3, substituted with one or more substituents independently selected from the group consisting of -Cl and -Br.
5. Y is absent, —O—, —OCH 2 --, --CH 2 -, -NH-, or -CH(NH 2 5. The compound according to claim 1, wherein
6. The compound of claim 5 , wherein Y is absent or O.
7. The compound of claim 6 , wherein Y is absent.
8. B is a 5- or 6-membered aromatic or heteroaromatic ring having zero to four heteroatom(s) that are absent or selected from among N and O, preferably N, said aromatic or heteroaromatic ring B optionally being -OR 4 The compound of any one of claims 1 to 7, substituted with one or more substituents independently selected from the group consisting of: and =O.
9. The compound according to any one of claims 1 to 8, wherein the aromatic ring or the aromatic heterocycle B is optionally substituted with one or more substituents independently selected from the group consisting of hydroxyl, methoxy and =O.
10. R 5 The compound according to any one of claims 1 to 9, wherein is selected from the group consisting of hydroxyl, methoxy and ethoxy.
11. R 5 The compound of claim 10, wherein is hydroxyl.
12. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(3-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-5-isoxazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-(4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(dimethylamino)-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(dimethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(diethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-tetrazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[2-(4H-1,2,4-triazol-4-yl)isonicotinoylamino]-3-hexenoic acid, (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-isopropyl-3-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(5-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(6-methyl-2-pyrazinyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[m-(5-chloro-2-pyridyloxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[6-(p-bromophenoxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid, (E)-2-{6-[p-(tert-butyl)phenoxy]nicotinoylamino}-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(p-cumenyloxy)isonicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(5-phenoxy-2-pyrazinylcarbonylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(5-methyl-2-pyridinyloxy)benzoylamino]-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[6-(4H-1,2,4-triazol-4-yl)-2-pyridylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid, (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-2-[3-(3,4-dichlorophenyl)-1-methyl-5-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(2-benzyl-4-methyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-methyl-2-(p-toluidino)-5-pyrimidinylcarbonylamino]-3-hexenoic acid, (E)-2-[2-(p-chlorophenylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[6-(p-chlorophenoxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[6-(p-tolyloxy)nicotinoylamino]-3-hexenoic acid, (E)-2-(6-benzylnicotinoylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(p-benzylbenzoylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(p-phenoxybenzoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenylnicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenylisonicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[6-(2-thienyloxy)nicotinoylamino]-3-hexenoic acid, (E)-2-(5-chloro-1-benzothiophen-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-chloro-2-indolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(1-thia-5-aza-2-indenylcarbonylamino)-3-hexenoic acid, (E)-2-(2-chloro-1-benzothiophen-6-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(2-chloro-6-indolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1,3-thiazol-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-1,3-thiazol-2-ylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-chloro-5-isothiazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3,4-dichloro-5-isothiazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(3-pyridyl)benzoylamino]-3-hexenoic acid, (E)-2-[m-(6-chloro-2-methyl-3-pyridyl)benzoylamino]-5,5-dimethyl-3-hexenoic acid, or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
13. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(3-pyridyl)-2-pyrrolylcarbonylamino]-3-hexenoic acid, (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-5-isoxazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-(4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(dimethylamino)-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(dimethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(diethylamino)-6-methyl-4-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-tetrazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[2-(4H-1,2,4-triazol-4-yl)isonicotinoylamino]-3-hexenoic acid, (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-isopropyl-3-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(5-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(6-methyl-2-pyrazinyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[m-(5-chloro-2-pyridyloxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[6-(p-bromophenoxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid, (E)-2-{6-[p-(tert-butyl)phenoxy]nicotinoylamino}-5,5-dimethyl-3-hexenoic acid, (E)-2-[2-(p-cumenyloxy)isonicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(5-phenoxy-2-pyrazinylcarbonylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(5-methyl-2-pyridinyloxy)benzoylamino]-3-hexenoic acid, 13. The compound of claim 12, selected from the group consisting of: or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
14. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-{4-[amino(2-pyridyl)methyl]-2-pyrrolylcarbonylamino}-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-(2-oxo-4-pyridyl)-4-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-2-[2-(dimethylamino)-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxyisonicotinoylamino)-3-hexenoic acid, (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-pyrimidinyloxy)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid, (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[1-methyl-3-(3-pyridyl)-5-pyrazolylcarbonylamino]-3-hexenoic acid, (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid, or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
15. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2,2,2-trifluoroacetyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(2-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[4-(4-pyridyl)-2-piperazinylcarbonylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isobutyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, 15. The compound of claim 14, selected from the group consisting of: or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
16. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(5-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(2-phenoxy-5-pyrimidinylcarbonylamino)-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-2-[p-(p-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-[p-(m-chlorophenoxy)benzoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(phenoxymethyl)benzoylamino]-3-hexenoic acid, (E)-2-(1-ethyl-3-isobutyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(3-isopropyl-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-[5-(3,4-dichlorophenyl)-1-methyl-3-pyrazolylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid, or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
17. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(1H-1,2,4-triazol-1-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, (E)-2-(4-bromo-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(3-pyridyloxy)benzoylamino]-3-hexenoic acid, (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, (E)-2-(2-isopropyl-5-pyrimidinylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid, (E)-2-(3-chloro-1-methyl-5-pyrazolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid, 17. The compound of claim 16, selected from the group consisting of: or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
18. 18. The compound of claim 17, wherein the compound is (E)-5,5-dimethyl-2[m-(1-imidazolyl)benzoylamino]-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
19. 18. The compound of claim 17, wherein the compound is (E)-2-(4-chloro-1-methyl-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
20. 18. The compound of claim 17, wherein the compound is (E)-2-(4-chloro-2-thienylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
21. 18. The compound of claim 17, wherein the compound is (E)-2-[6-(benzyloxy)nicotinoylamino]-5,5-dimethyl-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
22. 18. The compound of claim 17, wherein the compound is (E)-5,5-dimethyl-2-[p-(2-thienyl)benzoylamino]-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
23. 18. The compound of claim 17, wherein the compound is (E)-5,5-dimethyl-2-[m-(2-thienyl)benzoylamino]-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
24. 18. The compound of claim 17, wherein the compound is (E)-2-(4,5-dichloro-2-thienylamino)-5,5-dimethyl-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
25. The compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, (E)-5,5-dimethyl-2-[m-(4H-1,2,4-triazol-4-yl)benzoylamino]-3-hexenoic acid, (E)-5,5-dimethyl-2-(6-methyl-1H-1,5-diazainden-2-ylcarbonylamino)-3-hexenoic acid, (E)-2-(4-chloro-2-pyrrolylcarbonylamino)-5,5-dimethyl-3-hexenoic acid, 17. The compound of claim 16, selected from the group consisting of: or an enantiomer thereof, a diastereomer thereof, a racemate thereof, a prodrug thereof, or a pharma- ceutically acceptable salt thereof.
26. 26. The compound of claim 25, wherein the compound is (E)-2-[2-(dimethylamino)-4-methyl-5-pyrimidinylcarbonylamino]-5,5-dimethyl-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
27. 26. The compound of claim 25, wherein the compound is (E)-5,5-dimethyl-2-(6-phenoxynicotinoylamino)-3-hexenoic acid, or an enantiomer, a diastereomer, a racemate, a prodrug, or a pharma- ceutically acceptable salt thereof.
28. A pharmaceutical composition comprising a compound according to any one of claims 1 to 27, and at least one pharma- ceutically acceptable excipient, carrier or diluent.
29. A compound according to any one of claims 1 to 27 for use as a medicament.
30. A compound according to any one of claims 1 to 27 for use in the prevention or treatment of cancer.
31. A compound according to any one of claims 1 to 27 for use in the prevention or treatment of neurodegenerative diseases, psychiatric diseases, motor neuron diseases, peripheral neuropathy, pain, neuroinflammation, atherosclerosis, hyperlipidemia, cardiovascular diseases, dermatological related diseases, autoimmune diseases, preferably Alzheimer's disease and Parkinson's disease.
32. 11. An intermediate for producing the compound of claim 1, said intermediate comprising: (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexenoic acid, Ethyl (E)-2-{[(p-methoxyphenyl)methyl]amino}-5,5-dimethyl-3-hexanoate, and The intermediate is selected from the group consisting of ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate.
33. 33. The intermediate of claim 32, wherein the intermediate is ethyl (E)-2-amino-5,5-dimethyl-3-hexanoate.
Citation Information
Patent Citations
Decorative film and article to which the same is adhered
WO2018022568A1
